Kit for inducing stem cells to differentiate into NK cells, use of kit, and use of combination of NK cells and TMZ in treatment for TMZ drug-resistant gbm
By inducing stem cells to differentiate into NK cells through a specific culture medium combination and combining it with TMZ chemotherapy, the problems of low NK cell differentiation efficiency and GBM resistance were solved, thereby improving the killing ability of NK cells and the therapeutic effect of TMZ-resistant GBM.
Patent Information
- Application Number
- PCT/CN2024/078236
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-01
- Filing Date
- 2024-02-23
- Publication Date
- 2024-11-07
AI Technical Summary
In existing technologies, methods for inducing stem cells to differentiate into NK cells are inefficient, the number of NK cells obtained is limited, and the operation is complex, which is not conducive to the preparation of clinical-grade cell products. GBM is resistant to TMZ chemotherapy drugs, and existing immunotherapies have not achieved a breakthrough in the treatment of GBM.
A kit is provided containing a specific culture medium combination for inducing stem cell differentiation into NK cells, and for combining NK cells with TMZ chemotherapy drugs to enhance the therapeutic effect against TMZ-resistant GBM.
It improved the differentiation efficiency and quantity of NK cells, enhanced the killing ability against GBM, and especially the therapeutic effect against TMZ-resistant GBM.
Smart Images

Figure CN2024078236_07112024_PF_FP_ABST
Abstract
Description
Kit for inducing stem cell differentiation into NK cells and its application, and application of NK cells combined with TMZ in the treatment of TMZ-resistant GBM Technical Field
[0001] The present invention belongs to the field of biotechnology and relates to a kit for inducing stem cells to differentiate into natural killer cells and its application. The present invention also relates to the treatment of solid tumors by combining immune cells with chemotherapy drugs, and specifically to the synergistic treatment of TMZ-resistant GBM by combining NK cells with TMZ. Background Art
[0002] Natural killer (NK) cells are part of the innate immune system and play a crucial role in immune surveillance, host defense against viral infections, and combating tumor cells. Recent studies have also shown that NK cells are potential therapeutic targets for cancer treatment. In the human body, NK cells comprise 8-20% of lymphocytes. Unlike other lymphocytes (including B cells, T cells, and natural killer T (NKT) cells), NK cells do not express antigen-specific receptors such as clonal B cell receptors or the T cell receptor / CD3ε complex. Instead, NK cells function in an antigen-independent manner (typically without generating immune memory or long-term protective immunity). NK cells regulate their own cytotoxicity through activating and inhibitory receptors on their surface. Unlike T cells, NK cells retain their natural receptors to recognize and target tumor cells. Compared with T cells, NK cells do not require strict HLA (human leukocyte antigen) matching, so the risk of GVHD (graft-versus-host disease) is lower. In addition, in many current clinical trials, NK cells have not shown safety issues similar to cytokine release syndrome in T cell therapy, thus opening up the possibility of producing "off-the-shelf" allogeneic cell therapy products.
[0003] NK cells derived from peripheral blood and umbilical cord blood are affected by the donor and have limited cell sources. The state, quality and yield of the obtained cells are also different. In addition, T cell contamination may occur during the cell expansion process. Moreover, the state of the expanded NK cells will deteriorate after freezing. However, there are many problems with the current methods of inducing stem cells to differentiate into natural killer cells: the methods for producing NK cells derived from iPS cell differentiation include MEK inhibitors, GSK3 inhibitors and ROCK inhibitors, etc., but the efficiency of the differentiated NK cells is low and the number of NK cells obtained is limited; the method for producing NK cells derived from iPS cell differentiation in patent document CN107429230A is: hematopoietic progenitor cells are differentiated in the form of embryoid bodies 3D, and then CD34 is enriched. + CD45 +The cells are then differentiated into NK cells, and commercial culture media with uncertain composition and heterologous substances such as serum are used, which makes the operation process complicated and is not conducive to the preparation of subsequent clinical-grade cell products; Patent document CN The method for generating NK cells derived from iPS cell differentiation in 112608895A is as follows: first, EBs (embryoid bodies) are differentiated into permanent hematopoietic HPCs (hematopoietic progenitor cells). This process is followed by inoculating the EBs into a culture vessel coated with matrix protein to obtain permanent hematopoietic HPCs, which are then differentiated into NK cells. The efficiency of obtaining permanent hematopoietic HPCs by this method is low, and the differentiation of NK cells is greatly affected by the cell state of the early HPCs and the efficiency of the differentiated HPCs. In addition, the cells need to be subsequently inoculated into a culture vessel containing matrix protein, and the differentiation of NK cells will also be affected by the matrix protein. The method for generating NK cells derived from iPS cell differentiation in patent document CN113801846A is as follows: human induced pluripotent stem cells are inoculated into a wave bioreactor and a cell factory to obtain endothelial progenitor cells, and then the endothelial progenitor cells are induced to differentiate into NK progenitor cells, which are further differentiated into NK cells. In this differentiation system, endothelial progenitor cells have the potential to differentiate into multiple endothelial cells, increasing the risk that the efficiency of differentiation into NK cells will be affected by the external environment (such as the parameter settings of the bioreactor).
[0004] Gliomas are malignant tumors that develop in the brain or in nerves originating from the brain. The World Health Organization (WHO) classifies gliomas into grades I-IV based on pathological grading, with grade IV being glioblastoma (GBM). GBM is the most common and most aggressive central nervous system tumor in the brain. Currently, all standard treatments are ineffective, resulting in a poor prognosis, with a 5-year overall survival rate of only 6.8% (Ostrom QT, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100.). For newly diagnosed GBM, the current standard of care includes maximal safe tumor resection followed by radiotherapy (RT) and temozolomide (TMZ) combined with chemotherapy.
[0005] However, GBM is divided into sensitive and resistant types to TMZ. Patients with sensitive GBM have a relatively better prognosis with standard TMZ treatment, but almost all GBM will relapse. Once progression or recurrence begins, the median survival (OS) is only 6 to 9 months. The reason is that sensitive GBM tumor cells develop various strategies to escape the effects of TMZ and transform into resistant GBM. Ultimately, like primary resistant GBM, they resist the effects of TMZ, relapse, and metastasis, endangering their lives (Weller M, et al. Standards of care for treatment of recurrent glioblastoma—are we there yet? Neuro Oncol. 2013 Jan; 15(1): 4-27.). Therefore, new treatment strategies are urgently needed to treat TMZ-resistant GBM.
[0006] Immunotherapy, a novel anti-tumor therapy that utilizes adoptive immune cells or the autoimmune system, is transforming the treatment of various cancers. However, to date, immunotherapy has not achieved a breakthrough in GBM due to factors such as the high heterogeneity of GBM, heterogeneous target sites, and the low utilization of protein drugs due to the blood-brain barrier. New therapeutic strategies are needed in this field that utilize adoptive immune cells in combination with TMZ to improve the treatment of TMZ-resistant GBM.
[0007] Summary of the Invention
[0008] In a first aspect, the present invention provides a kit comprising a second culture medium, a fourth culture medium and a fifth culture medium; wherein the second culture medium is a basal culture medium comprising a BMP signaling pathway activator; the fourth culture medium is a basal culture medium comprising at least one, at least two, at least three or at least four of the following: a BMP signaling pathway activator, a vascular endothelial growth factor, a colony stimulating factor, and an interleukin; and the fifth culture medium is a basal culture medium comprising at least one, at least two, at least three, at least four, at least five or at least six of the following: a BMP signaling pathway activator, a vascular endothelial growth factor, a colony stimulating factor, an interleukin, a stem cell agonist, and a stem cell expander.
[0009] In one embodiment, the kit further comprises a third culture medium, which is a basal culture medium comprising at least one, at least two, or at least three of the following: a BMP signaling pathway activator, a growth factor, and a TGFβ / ALK inhibitor.
[0010] In one embodiment, the kit further comprises a first culture medium, which is a basal culture medium comprising a ROCK inhibitor.
[0011] In one embodiment, the second culture medium is a basal culture medium comprising a BMP signaling pathway activator and a GSK3 inhibitor.
[0012] In a second aspect, the present invention provides the use of the kit of the first aspect of the present invention in preparing embryoid bodies, preparing mesodermal cells, preparing hemogenic endothelial cells, preparing natural killer (NK) cells, preparing products for inducing stem cells to differentiate into embryoid bodies, preparing products for inducing stem cells to differentiate into mesodermal cells, preparing products for inducing stem cells to differentiate into hemogenic endothelial cells, and / or preparing products for inducing stem cells to differentiate into NK cells.
[0013] In a third aspect, the present invention provides a method for inducing stem cells to differentiate into natural killer (NK) cells, the method comprising the steps of using the kit of the first aspect of the present invention.
[0014] In one embodiment, the method comprises: step (1) culturing stem cells to obtain embryoid bodies; step (2) subjecting the embryoid bodies to mesoderm differentiation culture to obtain mesodermal cells; step (3) subjecting the mesoderm cells to hemogenic endothelial differentiation culture to obtain hemogenic endothelial cells; and step (4) culturing the hemogenic endothelial cells in the fourth culture medium and the fifth culture medium of the kit of the first aspect of the present invention to obtain NK cells.
[0015] In a fourth aspect, the present invention provides a natural killer (NK) cell, which is prepared by the kit of the first aspect of the present invention and / or the method of the third aspect of the present invention.
[0016] In a fifth aspect, the present invention provides a pharmaceutical composition comprising the NK cells of the fourth aspect of the present invention.
[0017] In a sixth aspect, the present invention provides use of the NK cell of the fourth aspect of the present invention or the pharmaceutical composition of the fifth aspect of the present invention in the preparation of a drug for preventing and / or treating tumors.
[0018] In a seventh aspect, the present invention provides a pharmaceutical combination for treating glioblastoma, comprising an active ingredient comprising natural killer (NK) cells and a chemotherapeutic agent, wherein the chemotherapeutic agent comprises temozolomide (TMZ).
[0019] In one embodiment, the glioblastoma is resistant to TMZ.
[0020] In one embodiment, the NK cells are unmodified NK cells.
[0021] In one embodiment, the NK cells include but are not limited to NK-92 cells, NK cells derived from peripheral blood or umbilical cord blood, NK cells derived from induced pluripotent stem cells (iPSCs) or embryonic stem cells.
[0022] In one embodiment, the NK cells are NK cells derived from induced pluripotent stem cells (iPSCs).
[0023] In one embodiment, the NK cells are unmodified NK cells derived from induced pluripotent stem cells.
[0024] In one embodiment, NK cells derived from induced pluripotent stem cells (iPSCs) are prepared by the kit of the first aspect of the present invention or the method of the third aspect of the present invention.
[0025] In one embodiment, NK cells derived from induced pluripotent stem cells (iPSCs) are prepared by the method described herein for inducing stem cell differentiation into natural killer cells. In one embodiment, the drug combination further comprises other chemotherapeutic agents selected from anticancer agents, metabolic antagonists, DNA demethylating agents, plant-derived antitumor agents, alkylating agents, antimetabolites, anticancer antibiotics, topoisomerase inhibitors, mitotic inhibitors, differentiation agents, and hormone therapy agents.
[0026] In one embodiment, the additional chemotherapeutic agent is selected from carmustine, lomustine, vorinostat, mebendazole, imatinib mesylate, AG119, or any therapeutic derivative thereof.
[0027] In one embodiment, the active ingredient does not comprise trimetrexate.
[0028] In one embodiment, the active ingredient does not comprise an immune checkpoint inhibitor.
[0029] In one embodiment, the pharmaceutical combination is a kit.
[0030] In an eighth aspect, the present invention further provides use of the drug combination according to the seventh aspect of the present invention in preparing a drug for treating glioblastoma.
[0031] In one embodiment, the chemotherapeutic agent is administered before, after, or simultaneously with the administration of NK cells.
[0032] In one embodiment, the chemotherapeutic agent is administered 8 to 72 hours before, 8 to 72 hours after, or both before and 8 to 72 hours after administration of the NK cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 is a schematic diagram of inducing human induced pluripotent stem cells to differentiate into natural killer cells and a cell differentiation diagram in Example 2: wherein A is a schematic diagram of inducing human induced pluripotent stem cells to differentiate into natural killer cells in Example 2; B is a cell morphology diagram (observed under a 4x objective lens) of hemogenic endothelial cells after 2 days of NK cell differentiation culture (iNK-D2, EB adherence D2) in Example 2; C is a cell morphology diagram (observed under a 10x objective lens) of hemogenic endothelial cells after 6 days of NK cell differentiation culture (iNK-D20) in Example 2.
[0034] FIG2 is a flow cytometry result of NK cells collected on the 13th, 16th and 20th days after NK cell differentiation culture of hemogenic endothelial cells in Example 2: A is the CD45 of NK cells collected on the 13th day after NK cell differentiation culture of hemogenic endothelial cells in Example 2. + CD56 + Figure 2 shows the results of cell detection; B is the CD45 of NK cells collected on the 16th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. + CD56 + Figure 2 shows the CD45 expression of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells. + CD3 - Cell detection result diagram; D is the CD56 of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2 + CD3 - Figure 2 shows the results of cell detection; E is the CD45 of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. + CD56 + Figure 2 shows the results of cell detection; F is the CD45 of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. + CD94 + Cell detection result diagram; G is the CD56 of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2 + CD94 + Cell detection results diagram.
[0035] FIG3 is a flow cytometry result of NK cells collected on the 20th day after NK cell differentiation culture of hemogenic endothelial cells in Example 2: A is the CD3 - CD45 + CD56 +Figure 2 shows the results of cell detection; B is the CD3 - CD16 - Figure 2 shows the results of cell detection; C is the CD3 - Nkp46 + Cell detection result diagram; D is the CD3 in NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2 - CD56 + Nkp44 + Cell detection result diagram; E is the CD3 in NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. - CD56 + Nkp30 + Figure 2 shows the results of cell detection; F is the CD3 in NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. - CD56 + Nkp44 + Nkp30 + Cell detection results diagram.
[0036] Figure 4 is a flow cytometry result of NK cells collected on the 20th day after NK cell differentiation culture of hemogenic endothelial cells in comparative example 2: A is the CD45 + CD3 - Cell detection results diagram; B is the CD43 of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. + CD3 - Figure 2 shows the results of cell cell detection; C is the CD45 of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. + CD56 + Cell detection results; D is the NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. + CD94 + Figure 2 shows the results of cell cell detection; E is the NK cell CD56 collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2. + CD94 + Cell cell detection results diagram.
[0037] Figure 5 is a flow cytometry result of NK cells collected on the 20th day after NK cell differentiation culture of hemogenic endothelial cells in comparative example 4: A is the CD45 + CD3 - Cell cell detection results diagram; B is the NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 4. + CD3 - Figure 4 shows the results of cell cell detection; C is the CD45 in NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 4. + CD56 + Cell cell detection result diagram; D is the NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 4. + CD94 + Figure 4 shows the results of cell cell detection; E is the NK cell CD56 collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 4. + CD94 + Cell cell detection results diagram.
[0038] Figure 6 is a flow cytometry result diagram of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in comparative example 6, example 4-1, example 4-3, example 4-2, and example 2: wherein A is a flow cytometry result diagram of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in comparative example 6; B is a flow cytometry result diagram of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in example 4-1; C is a flow cytometry result diagram of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in example 4-3; D is a flow cytometry result diagram of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in example 4-2; E is a flow cytometry result diagram of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in comparative example 6, example 4-1, example 4-3, example 4-2, and example 2 + CD56 + Bar graph of cell proportions.
[0039] Figure 7 is a bright field image of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 6, Example 4-1, Example 4-3, and Example 4-2: wherein, A is a bright field image of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 6; B is a bright field image of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 4-1; C is a bright field image of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 4-3; D is a bright field image of NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 4-2.
[0040] FIG8 is a graph showing the results of IFN-γ expression in the NK cells of Example 2 and peripheral blood-derived NK cells (PB-NK) treated under the same conditions.
[0041] FIG9 is a graph showing the killing effect of NK cells in Example 2 and peripheral blood-derived NK cells (PB-NK) treated under the same conditions on Hela cells.
[0042] FIG10 is a schematic diagram of the process of the NK cell in vivo killing experiment in Example 4.
[0043] FIG. 11 is a graph showing the results of the NK cell killing experiment in vivo in Example 4.
[0044] FIG. 12 is a graph showing the expansion folds of different batches of NK cells after differentiation in Example 5.
[0045] FIG. 13 is a graph showing the comparison of cell viability before and after cryopreservation of NK cells in Example 5.
[0046] FIG. 14 (AD) shows the sensitivity responses of different GBM cell lines to TMZ.
[0047] Figure 15 (AB) shows the effect of TMZ on cell cycle arrest in different GBM cell lines.
[0048] FIG16 shows that TMZ treatment for 48 hours induced upregulation of the expression of various immune ligands in drug-resistant GBM tumor cells.
[0049] FIG. 17 shows the characterization results of NK cells differentiated from iPSCs in vitro.
[0050] FIG. 18 (AB) shows the results of the degranulation activity test of iPSC-NK cells combined with TMZ in killing GBM. FIG.
[0051] FIG19 shows the killing activity of iPSC-NK cells combined with TMZ against drug-resistant GBM (T98G).
[0052] FIG20 shows the characterization results of NK92 cell line and PB-NK cells.
[0053] FIG21 shows the killing activity of NK cells from different sources combined with TMZ against drug-resistant GBM. Specific implementation plan
[0054] General Definitions and Terminology
[0055] All patents, patent applications, scientific publications, manufacturer's instructions and guidelines, etc., cited herein, whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein should be construed as an admission that the present disclosure is not entitled to antedate such publication.
[0056] Unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the terms related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, and microbiology used herein are terms widely used in the corresponding fields (see, for example, Molecular Cloning: A Laboratory Manual, 2 nd Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989). Meanwhile, for a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0057] As used herein, the expressions "comprise," "include," "contain," and "have" are open ended and mean the inclusion of the listed elements, steps, or components but not the exclusion of other unlisted elements, steps, or components. The expression "consisting of excludes any element, step, or component not specified. The expression "consisting essentially of means that the scope is limited to the specified elements, steps, or components, plus optional elements, steps, or components that do not significantly affect the basic and novel properties of the claimed subject matter. It should be understood that the expressions "consisting essentially of" and "consisting of are encompassed within the meaning of the expression "comprising."
[0058] As used herein, the singular forms "a," "an," or "the" include plural referents unless the context indicates otherwise. The terms "one or more" or "at least one" encompass 1, 2, 3, 4, 5, 6, 7, 8, 9 or more.
[0059] Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated into the specification as if it were individually recited herein. Unless expressly indicated to the contrary, values or ranges recited herein are modified by "about" to mean ±20%, ±10%, ±5%, or ±3% of the recited or claimed value or range.
[0060] The term "pluripotent cell" refers to a cell that is capable of self-renewal and proliferation while remaining in an undifferentiated state and that can be induced to differentiate into specialized cell types under appropriate conditions.
[0061] As used herein, the term "pluripotent stem cell" has the potential to differentiate into any one of the following three germ layers: endoderm (e.g., gastric junction, gastrointestinal tract, lung, etc.), mesoderm (e.g., muscle, bone, blood, urogenital tissue, etc.), or ectoderm (e.g., epidermal tissue and nervous system tissue). The term "pluripotent stem cell" as used herein also includes "induced pluripotent stem cells" or "iPSCs," which are pluripotent stem cells constructed by reprogramming non-pluripotent cells by introducing specific transcription factors. Exemplary human pluripotent stem cell lines include H1 human pluripotent stem cell lines and H9 human pluripotent stem cell lines. Additional exemplary pluripotent stem cell lines include those available through the National Institutes of Health Human Embryonic Stem Cell Registry and the Howard Hughes Medical Institute HUES collection (e.g., Cowan CA, et al. Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med. 2004 Mar 25; 350 (13): 1353-6.). Pluripotent stem cells can be induced to differentiate into different cells, which can be used for different prevention or treatment purposes, to prevent or treat different diseases. As will be appreciated by those skilled in the art, differentiation methods depend on the desired cell type using known technology. For example, cells can be suspended for differentiation and then made into a gel matrix form, such as matrigel, gelatin or fibrin / thrombin form, to promote cell survival. Differentiation can usually be determined as known in the art by assessing the presence of cell-specific markers. For example, cells can be differentiated into cardiomyocytes, neurons, glial cells, endothelial cells, T cells, NK cells, NKT cells, macrophages, hematopoietic progenitor cells, mesenchymal cells, islet cells, chondrocytes, retinal pigment epithelial cells, kidney cells, hepatocytes, thyroid cells, skin cells, blood cells or epithelial cells under certain differentiation conditions. In some embodiments, iPSC is differentiated into NK cells.
[0062] NK cells derived from iPSCs are also referred to herein as iNK cells.Herein, the terms "iNK cells", "iPSC-NK cells" and "NK cells derived from induced pluripotent stem cells (iPSCs)" are used interchangeably.
[0063] As used herein, the term "totipotent" refers to the ability of a cell to form a complete organism. For example, in mammals, only the fertilized egg and the first cleavage stage blastomere are totipotent. In some embodiments, the pluripotent stem cells described herein do not have totipotency and will not form a complete organism.
[0064] The cells can be from, for example, humans or non-human mammals. Exemplary non-human mammals include, but are not limited to, mice, rats, cats, dogs, rabbits, guinea pigs, hamsters, sheep, pigs, horses, cattle, and non-human primates. In some embodiments, the cells are from adults or non-human mammals. In some embodiments, the cells are from newborn humans, adults, or non-human mammals.
[0065] As used herein, the term "subject" or "patient" refers to any animal, such as a domesticated animal, a zoo animal, or a human. A "subject" or "patient" can be a mammal, such as a dog, a cat, a bird, livestock, or a human. Specific examples of "subject" and "patient" include, but are not limited to, individuals (particularly humans) with diseases or conditions related to the liver, heart, lungs, kidneys, pancreas, brain, nervous tissue, blood, bones, bone marrow, and the like. In some embodiments, "subject" and "patient" refer to individuals (particularly humans) with glioblastoma. In some preferred embodiments, "subject" and "patient" refer to individuals (particularly humans) with TMZ-resistant glioblastoma.
[0066] In this article, the terms "reduce" and "reduce" are generally used to represent a statistically significant amount of reduction. However, for the avoidance of doubt, "reduce", "reduce" include reducing by at least 10% compared to a reference level, such as reducing by at least about 20% or at least about 30% compared to a reference level, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including 100% reduction (i.e., a level that is not present compared to a reference sample), or any reduction between 10-100%.
[0067] As used herein, the term "increase" is generally used to refer to an increase by a statistically significant amount; for the avoidance of any doubt, the term "increase" refers to an increase of at least 10% compared to a reference level, such as an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including a 100% increase or any increase between 10-100%, or at least about 2-fold, or at least about 3-fold, or at least about 4-fold, or at least about 5-fold or at least about 10-fold compared to a reference level, or any increase between 2-fold and 10-fold or greater than 10-fold.
[0068] In this article, the term "NK cell" or "natural killer cell (natural killer cell)" is used interchangeably. NK cells are effector cells of the innate immune system and belong to the family of innate lymphocytes (ILCs), characterized by the presence of CD56 and the absence of CD3 surface markers. Most NK cells are located in peripheral blood, lymph nodes, spleen, and bone marrow. NK cells can protect the host by killing infected, foreign, stressed, or transformed cells. They can kill target cells in the absence of specific antigen stimulants and are not restricted by MHC classes, wherein the target cells can be tumor cells or cells carrying viruses. Currently, in preclinical and clinical development strategies, adoptive immunotherapy, direct stimulation, NK cells are recruited to the tumor microenvironment (TME), and methods such as blocking inhibitory receptors that limit NK cell function enhance the anti-tumor function of NK cells (see, for example, Bald T, et al. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020 Aug; 21 (8): 835-847.).
[0069] As used herein, the terms "adoptive cell transfer therapy," "adoptive immune cell therapy," "adoptive immune cell therapy," or "adoptive cell therapy" are an immune cell therapy method that improves immune function by modifying and amplifying immune cells in vitro, and then injecting them into the patient's body to exert an anti-tumor effect. These immune cells can be from allogeneic or homologous sources. Allogeneic adoptive immunotherapy refers to the transfer of immune cells from an allogeneic (different individual) to a patient. Allogeneic adoptive immunotherapy refers to the collection, amplification, and transfer of the patient's own immune cells. These immune cells can be natural killer cells, T cells, or lymphocytes, etc.
[0070] As used herein, the term "glioblastoma" or "glioblastoma" is the most common malignant primary brain tumor, accounting for approximately 57% of gliomas and 48% of primary malignant central nervous system (CNS) tumors (see, for example, Tan AC, et al. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020 Jul; 70(4): 299-312.). It has problems such as drug resistance, poor patient prognosis and short survival during treatment. Currently, there are few clinical drugs for the treatment of GBM, mainly temozolomide (TMZ), carmustine, lomustine and bevacizumab. Among them, TMZ is the most commonly used first-line drug in clinical practice. However, the effect of GBM on TMZ is divided into sensitive and resistant types. The term "sensitive GBM" refers to GBM that is sensitive to standard TMZ treatment and has a relatively better prognosis. However, tumors that were originally sensitive to chemotherapy usually gradually develop resistance to drugs, so sensitive GBM tumor cells will also develop various strategies to escape the effects of TMZ and eventually turn into drug-resistant GBM. The term "drug-resistant GBM" means that GBM is resistant to TMZ and can resist the effects of TMZ. Drug resistance is not caused by a single factor, but may be related to many aspects such as the DNA mismatch repair system, the expression of O6-methylguanine-DNA methyltransferase, and drug penetration in the blood-brain barrier (see, for example, Ortiz R, et al. Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Curr Neuropharmacol. 2021; 19(4): 513-537.).
[0071] As used herein, the term "chemotherapeutic agent" refers to a compound or derivative thereof that can interact with cancer cells, thereby reducing the proliferative state of the cells and / or killing the cells, for example, by impairing cell division or DNA synthesis, or effectively targeting rapidly dividing cells by damaging DNA. Examples of chemotherapeutic agents include, but are not limited to, anticancer agents, metabolic antagonists, DNA demethylating agents, plant-derived antitumor agents, alkylating agents, antimetabolites, anticancer antibiotics, topoisomerase inhibitors, mitotic inhibitors, differentiation agents, hormonal therapeutic agents, and combinations thereof.
[0072] As used herein, the term "alkylating agent" refers to a class of highly reactive chemical compounds with active alkyl groups that can be converted into electron-deficient, reactive intermediates that rapidly form covalent bonds with numerous cellular substances with affinity. Alkylating agents can covalently bind to electron-rich groups (e.g., amino, sulfhydryl, hydroxyl, carboxyl, and phosphate groups) in cellular biomacromolecules (e.g., DNA, RNA, and enzymes), deactivating them, causing DNA breakage, or leading to base mispairing during DNA replication, thereby disrupting DNA structure and function and causing tumor cell death.
[0073] As used herein, the term "temozolomide (TMZ)" is an oral alkylating prodrug that transfers a methyl group to the purine bases of DNA (O6-guanine; N7-guanine and N3-adenine). It is often used in conjunction with radiotherapy as part of the first-line treatment of malignant glioma. The chemical formula of TMZ is C6H6N6O2, and its chemical structure is shown below. Its chemical name is 3,4-dihydro-3-methyl-4-oxoimidazolo[5,1-d]-unsymmetrical-tetrazolyl-8-amide. The main advantages of TMZ are its high oral bioavailability (almost 100%, although the concentration found in cerebrospinal fluid is approximately 20% of the plasma concentration of TMZ), its lipophilicity and small size, which enable it to cross the blood-brain barrier (see, e.g., Ortiz R, et al. Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Curr Neuropharmacol. 2021; 19(4): 513-537.).
[0074] As used herein, any form of administration of "combination," "combination therapy," and / or a "combination therapeutic regimen" refers to at least two therapeutically active drugs or compositions, or a combination of drugs comprising at least two therapeutically active ingredients, which may be administered simultaneously in separate or combined formulations, or sequentially at different times separated by minutes, hours, or days, but which act together in some manner to provide the desired therapeutic response.
[0075] The term "differentiation" is the process by which a less specialized cell forms progeny of at least one new, more specialized cell type.
[0076] The term "embryoid body", i.e., embryoid body or aggregate, refers to a homogeneous or heterogeneous cell cluster comprising differentiated cells, partially differentiated cells and / or pluripotent stem cells cultured in suspension. In order to summarize some of the clues inherent to in vivo differentiation, certain aspects of the present invention can use three-dimensional embryoid bodies as an intermediate step. At the beginning of cell aggregation, differentiation can be initiated and cells can begin to reproduce embryonic development to a limited extent. Although they cannot form trophectoderm tissue, almost all other types of cells present in an organism can develop. The present invention can further promote the differentiation of hematopoietic progenitor cells after embryoid body formation.
[0077] The term "basal medium" refers to a culture medium with defined chemical composition, including but not limited to basal cell culture media such as IMDM (Iscove's Modified Dulbecco's Medium), Eagle's Basal Medium (BME), MEM, DMEM, Ham's F-12, RPMI1640, Fischer's, E8, mTESR, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF, StemMACS iPS Brew, Stem-Partner ACF, TeSR-AOF, and TeSR2.
[0078] The term "multiple colony-stimulating factor" is also known as interleukin-3. It is primarily produced by activated Z or T cell clones. It contains 13 amino acid residues and acts as an immunomodulator, stimulating the proliferation and differentiation of pluripotent stem cells and various progenitor cells.
[0079] The term "stem cell factor" is also known as mast cell growth factor (MGF), Kit ligand (KL), and Steel factor (SLF). It is an acidic glycoprotein produced by stromal cells in the bone marrow microenvironment. Its glycosyl groups are attached to the N and O groups of the peptide bond. It has a molecular weight of 31,000-36,000 and is composed of two identical subunits bound non-covalently. Its isoelectric point (PI) is 3.8. SCF has a total of 273 amino acids. The amino acids -25 to -1 are the signal peptide, +1 to +189 are the extracellular domain, +190 to +216 are the transmembrane domain, and +217 to +248 are the cytoplasmic domain. Mouse and human SCF share 83% homology.
[0080] The term "vitamin C" includes vitamin C or its various salt forms or various derivatives thereof.
[0081] The term "UM171" includes UM171 (CAS No.: 1448724-09-1) or various forms of salts or various forms of derivatives thereof.
[0082] The term "SR1" includes SR1 (StemRegenin 1, CAS No.: 1227633-49-9) or its various forms of derivatives.
[0083] The term "glutamine" refers to L-glutamine, which is an amino acid encoded in protein synthesis and a non-essential amino acid for mammals. In the present invention, it is used as an essential supplement for cell culture.
[0084] The term "SB431542" also includes SB431542 and salts thereof, especially pharmaceutically acceptable salts.
[0085] The term "CHIR99021" includes CHIR99021 and salts thereof, especially pharmaceutically acceptable salts.
[0086] The term "Y-27632" also includes Y-27632 and its salts, especially pharmaceutically acceptable salts. A preferred pharmaceutically acceptable salt is Y-27632 2HCl.
[0087] The term "fibroblast growth factor" refers to a polypeptide secreted by the pituitary gland and hypothalamus that can promote fibroblast mitosis, mesoderm cell growth, and angiogenesis. It plays a role in wound healing and limb regeneration. There are two types of fibroblast growth factor: acidic (pI 5.6) and basic (pI 9.6), namely aFGF and bFGF.
[0088] The term "bone morphogenetic protein 4" refers to bone morphogenetic protein-4, BMP4, which regulates the proliferation and differentiation of various cells during embryonic development.
[0089] The term "B27 Medium Supplement without Vitamin A" is custom A culture medium supplement that does not contain vitamin A. Vitamin A (retinol) can be converted into retinoic acid, which can induce the differentiation of stem cells into neural cells. This vitamin A-free formula is ideal for stem cell culture.
[0090] Cell detection markers
[0091] The developmental stages of NK cells are mainly based on the expression levels of CD117, CD45, CD56 and CD94. Increased expression of CD56 is the key to NK maturation, followed by CD94 / NKG2A expression. Therefore, CD45 is usually selected during the differentiation process of NK. + CD56+ The expression of CD3 indicates the stage of differentiation, and the negative expression of CD3 indicates whether there is T cell interference in the differentiation system.
[0092] CD45: Cell surface phosphatase CD45 plays a role in NK cell development and intracellular signal transduction of activating receptors and is a key enzyme in inducing NK cell responses.
[0093] CD56: also known as neural cell adhesion molecule, it is a 175-185kDa glycoprotein belonging to the immunoglobulin superfamily C2 group, mainly expressed on human NK cells and a few MHC-mediated T lymphocytes, with an expression rate of more than 95% on the surface of human NK cells. It is an important marker on the surface of NK cells. NK cells are mainly characterized by CD3 - CD56 + Lymphocyte population.
[0094] CD3: The signaling component of the T cell receptor (TCR) complex, used to indicate whether there is T cell interference in the NK differentiation process, because some T cells can also express NK cell surface markers.
[0095] CD94: CD94 exists on the surface of NK cells mainly in the form of homotypic or heterotypic forms with NKG2A, and is a sign of the maturation of differentiated NK cells.
[0096] NKp30: NKp30 belongs to the CD28 family and is a member of the immunoglobulin superfamily (IgSF). It is expressed exclusively on the surface of NK cells and is a unique marker for NK cells. Its ligand is B7-H6, and its function is to activate NK cells. As an NK cell activating receptor, it plays a crucial role in immune surveillance and killing of tumors and pathogen-infected cells by binding to its corresponding ligand.
[0097] NKp44: NKp44 is a member of the immunoglobulin superfamily (IgSF) and is expressed exclusively on the surface of activated NK cells. It serves as a specific marker for activated NK cells, with a single V-shaped extracellular domain. While its cytoplasmic domain lacks an ITAM motif, its transmembrane domain contains positively charged lysines. This allows it to non-covalently bind to DAP12 homodimers, which also have negatively charged aspartic acid residues in their transmembrane domains and ITAM motifs in their cytoplasmic domains, thereby transducing activation signals. NKp44 is expressed only after NK cells are activated, further amplifying the signal.
[0098] NKp46: NKp46 is expressed on the surface of all NK cells (including mature, immature, resting, and activated NK cells). Its extracellular region contains two Ig-like domains. NKp46 has a shorter cytoplasmic region and a positively charged arginine in its transmembrane region. This allows it to non-covalently bind to CD3ζζ homodimers, which contain negatively charged aspartic acid in their transmembrane region and an ITAM motif in their cytoplasmic region, thereby transducing activation signals.
[0099] As used herein, the term "first culture medium" and similarly used terms such as "second culture medium," "third culture medium," "fourth culture medium," and "fifth culture medium" are used solely for differentiation purposes and are not intended to limit the order in which these media are used. These terms may be the same or different in different protocols.
[0100] Unless otherwise stated, all methods described herein can be performed in any suitable order.
[0101] Reagent test kit
[0102] In a first aspect, the present invention provides a kit comprising: a second culture medium, a fourth culture medium and a fifth culture medium; wherein the second culture medium is a basal culture medium comprising a BMP signaling pathway activator; the fourth culture medium is a basal culture medium comprising at least one, at least two, at least three or at least four of the following: a BMP signaling pathway activator, a vascular endothelial growth factor, a colony stimulating factor interleukin; and the fifth culture medium is a basal culture medium comprising at least one, at least two, at least three, at least four, at least five or at least six of the following: a BMP signaling pathway activator, a vascular endothelial growth factor, a colony stimulating factor, an interleukin, a stem cell agonist, and a stem cell expander.
[0103] In some embodiments, the kit is a kit for inducing stem cells to differentiate into natural killer cells.
[0104] In one embodiment, the second culture medium is a basal culture medium comprising a BMP signaling pathway activator and a GSK3 inhibitor.
[0105] In one embodiment, the BMP signaling pathway activator in the second culture medium comprises at least one of BMP2, BMP4, SB4, SJ000291942, SJ000063181, SJ000370178, isoliquiritigenin, diosmetin, apigenin, and biochanin. In a preferred embodiment, the BMP signaling pathway activator in the second culture medium comprises BMP4.
[0106] In one embodiment, the GSK-3 inhibitor in the second culture medium comprises at least one of a GSK-3α inhibitor and a GSK-3β inhibitor. In a preferred embodiment, the GSK-3 inhibitor in the second culture medium comprises at least one of B216763, TWS119, NP031112, SB216763, CHIR-98014, AZD2858, AZD1080, SB415286, LY2090314, and CHIR-99021. In a more preferred embodiment, the GSK-3 inhibitor in the second culture medium comprises CHIR-99021.
[0107] In one embodiment, the concentration of the BMP signaling pathway activator in the second culture medium is 1-100 ng / mL; preferably 2-50 ng / mL; more preferably 20 ng / mL.
[0108] In one embodiment, the concentration of the GSK-3 inhibitor in the second culture medium is 0.1-10 μM; preferably 1-10 μM; more preferably 3 μM.
[0109] In one embodiment, the basal medium of the second culture medium comprises at least one of IMDM (Iscove's Modified Dulbecco's Medium), Eagle's Basal Medium (BME), MEM, DMEM, Ham's F-12, RPMI1640, Fischer's medium, and DMEM / F12. In a preferred embodiment, the basal medium of the second culture medium comprises RPMI1640.
[0110] In one embodiment, the basal medium of the second culture medium comprises at least one, at least two, at least three, or at least four of the following: non-essential amino acids, glutamine, vitamin C, and B27 medium supplement. In a preferred embodiment, the basal medium of the second culture medium comprises non-essential amino acids, glutamine, vitamin C, and B27 medium supplement.
[0111] In one embodiment, the B27 medium supplement is a B27 medium supplement without vitamin A.
[0112] In one embodiment, the concentration of non-essential amino acids in the second culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0113] In one embodiment, the concentration of glutamine in the second culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0114] In one embodiment, the concentration of vitamin C in the second culture medium is 10-100 μg / mL; preferably 20-50 μg / mL, more preferably 50 μg / mL.
[0115] In one embodiment, the concentration of the B27 medium supplement in the second culture medium is 1%-10% (v / v), preferably 2% (v / v).
[0116] In the present invention, the second culture medium is used to induce embryoid bodies to differentiate into mesodermal cells.
[0117] In one embodiment, the BMP signaling pathway activator in the fourth culture medium and / or the fifth culture medium comprises at least one of BMP2, BMP4, SB4, SJ000291942, SJ000063181, SJ000370178, isoliquiritigenin, diosmetin, apigenin, and biochanin. In a preferred embodiment, the BMP signaling pathway activator in the fourth culture medium and / or the fifth culture medium comprises BMP4.
[0118] In one embodiment, the vascular endothelial growth factor in the fourth culture medium and / or the fifth culture medium comprises at least one of VEGF-A, VEGF-165, VEGF-183, VEGF-110, VEGF-121, VEGF-B, VEGF-C, VEGF-D, and VEGF-E. In a preferred embodiment, the vascular endothelial growth factor in the fourth culture medium and / or the fifth culture medium comprises VEGF-165.
[0119] In one embodiment, the colony stimulating factors in the fourth culture medium include at least one of G-CSF (granulocyte colony stimulating factor), M-CSF (macrophage colony stimulating factor), GM-CSF (recombinant human granulocyte-macrophage colony stimulating factor), multi-CSF (multiple colony stimulating factor, also known as IL-3), EPO (erythropoietin), TPO, SCF, and F1T3L. In a preferred embodiment, the colony stimulating factors in the fourth culture medium include at least one of IL-3, SCF, and F1T3L. In a more preferred embodiment, the colony stimulating factors in the fourth culture medium include IL-3, SCF, and F1T3L.
[0120] In one embodiment, the colony stimulating factors in the fifth culture medium include at least one of G-CSF (granulocyte colony stimulating factor), M-CSF (macrophage colony stimulating factor), GM-CSF (recombinant human granulocyte-macrophage colony stimulating factor), multi-CSF (multiple colony stimulating factor, also known as IL-3), EPO (erythropoietin), TPO, SCF, and F1T3L. In a preferred embodiment, the colony stimulating factors in the fifth culture medium include at least one of SCF and F1T3L. In a more preferred embodiment, the colony stimulating factors in the fifth culture medium include SCF and F1T3L.
[0121] In one embodiment, the interleukin in the fourth culture medium and / or the fifth culture medium comprises at least one of IL-1, IL-2, IL-6, IL-7, IL-12, IL-15, IL-18, IL-21, and IL-27. In a preferred embodiment, the interleukin in the fourth culture medium and / or the fifth culture medium comprises at least one of IL-7 and IL-15. In a more preferred embodiment, the interleukin in the fourth culture medium and / or the fifth culture medium comprises IL-7 and IL-15.
[0122] In one embodiment, the stem cell agonist in the fifth culture medium comprises at least one of UM171 and UM729. In a preferred embodiment, the stem cell agonist comprises UM171.
[0123] In one embodiment, the stem cell expander of the fifth culture medium comprises at least one of SR1 and PD98059. In a preferred embodiment, the stem cell expander comprises SR1.
[0124] In one embodiment, the concentration of the BMP signaling pathway activator in the fourth culture medium is 1-50 ng / mL; preferably 1-10 ng / mL; more preferably 5 ng / mL.
[0125] In one embodiment, the concentration of vascular endothelial growth factor in the fourth culture medium is 5-50 ng / mL; preferably 5-20 ng / mL; more preferably 10 ng / mL.
[0126] In one embodiment, the concentration of the colony stimulating factor in the fourth culture medium is 7-200 ng / mL; preferably 16-80 ng / mL; more preferably 35 ng / mL.
[0127] In one embodiment, the concentration of IL-3 in the fourth culture medium is 1-50 ng / mL; preferably 1-10 ng / mL; more preferably 5 ng / mL.
[0128] In one embodiment, the concentration of SCF in the fourth culture medium is 5-100 ng / mL; preferably 10-50 ng / mL; more preferably 20 ng / mL.
[0129] In one embodiment, the concentration of FLT3L in the fourth culture medium is 1-50 ng / mL; preferably 5-20 ng / mL; more preferably 10 ng / mL.
[0130] In one embodiment, the concentration of interleukin in the fourth culture medium is 2-100 ng / mL; preferably 15-70 ng / mL; more preferably 30 ng / mL.
[0131] In one embodiment, the concentration of IL15 in the fourth culture medium is 1-50 ng / mL; preferably 5-20 ng / mL; more preferably 10 ng / mL.
[0132] In one embodiment, the concentration of IL7 in the fourth culture medium is 1-50 ng / mL; preferably 10-50 ng / mL; more preferably 20 ng / mL.
[0133] In one embodiment, the concentration of the BMP signaling pathway activator in the fifth culture medium is 1-50 ng / mL; preferably 5-10 ng / mL; more preferably 5 ng / mL.
[0134] In one embodiment, the concentration of vascular endothelial growth factor in the fifth culture medium is 5-50 ng / mL; preferably 5-20 ng / mL; more preferably 10 ng / mL.
[0135] In one embodiment, the concentration of the colony stimulating factor in the fifth culture medium is 6-150 ng / mL; preferably 15-70 ng / mL; more preferably 30 ng / mL.
[0136] In one embodiment, the concentration of SCF in the fifth culture medium is 5-100 ng / mL; preferably 10-50 ng / mL; more preferably 20 ng / mL.
[0137] In one embodiment, the concentration of FLT3L in the fifth culture medium is 1-50 ng / mL; preferably 5-20 ng / mL; more preferably 10 ng / mL.
[0138] In one embodiment, the concentration of interleukin in the fifth culture medium is 2-100 ng / mL; preferably 15-70 ng / mL; more preferably 30 ng / mL.
[0139] In one embodiment, the concentration of IL15 in the fifth culture medium is 1-50 ng / mL; preferably 5-20 ng / mL; more preferably 10 ng / mL.
[0140] In one embodiment, the concentration of IL7 in the fifth culture medium is 1-50 ng / mL; preferably 10-50 ng / mL; more preferably 20 ng / mL.
[0141] In one embodiment, the concentration of the stem cell agonist in the fifth culture medium is 0.5-10 μM; preferably 0.5 μM-5 μM; more preferably 1 μM.
[0142] In one embodiment, the concentration of the stem cell expander in the fifth culture medium is 0.5-10 μM; preferably 0.5 μM-5 μM; more preferably 1 μM.
[0143] In one embodiment, the basal medium of the fourth culture medium comprises at least one of IMDM (Iscove's Modified Dulbecco's Medium), Eagle's Basal Medium (BME), MEM, DMEM, Ham's F-12, RPMI1640, Fischer's medium, and DMEM / F12. In a preferred embodiment, the basal medium of the fourth culture medium comprises IMDM (Iscove's Modified Dulbecco's Medium).
[0144] In one embodiment, the basal medium of the fourth culture medium comprises at least one, at least two, at least three, at least four, at least five, or at least six of the following: non-essential amino acids, glutamine, vitamin C, B27 medium supplement, and N-acetyl-L-cysteine (NAC). In a preferred embodiment, the basal medium of the fourth culture medium comprises non-essential amino acids, glutamine, vitamin C, B27 medium supplement, and N-acetyl-L-cysteine (NAC).
[0145] In one embodiment, the B27 medium supplement is a B27 medium supplement without vitamin A.
[0146] In one embodiment, the concentration of non-essential amino acids in the fourth culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0147] In one embodiment, the concentration of glutamine in the fourth culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0148] In one embodiment, the concentration of vitamin C in the fourth culture medium is 10-100 μg / mL; preferably 20-50 μg / mL, more preferably 50 μg / mL.
[0149] In one embodiment, the concentration of the B27 medium supplement in the fourth culture medium is 1-10% (v / v), preferably 2% (v / v).
[0150] In one embodiment, the concentration of N-acetyl-L-cysteine in the fourth culture medium is 1-100 μM; preferably 10-50 μM, more preferably 30 μM.
[0151] In one embodiment, the basal medium of the fifth culture medium comprises at least one of IMDM (Iscove's Modified Dulbecco's Medium), Eagle's Basal Medium (BME), MEM, DMEM, Ham's F-12, RPMI1640, Fischer's medium, and DMEM / F12. In a preferred embodiment, the basal medium of the fifth culture medium comprises IMDM (Iscove's Modified Dulbecco's Medium).
[0152] In one embodiment, the base medium of the fifth culture medium comprises at least one, at least two, at least three, at least four, at least five, or at least six of the following: non-essential amino acids, glutamine, vitamin C, B27 medium supplement, and N-acetyl-L-cysteine (NAC). In a preferred embodiment, the base medium of the fifth culture medium comprises non-essential amino acids, glutamine, vitamin C, B27 medium supplement, and N-acetyl-L-cysteine (NAC).
[0153] In one embodiment, the B27 medium supplement is a B27 medium supplement without vitamin A.
[0154] In one embodiment, the concentration of non-essential amino acids in the fifth culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0155] In one embodiment, the concentration of glutamine in the fifth culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0156] In one embodiment, the concentration of vitamin C in the fifth culture medium is 10-100 μg / mL; preferably 20-50 μg / mL, more preferably 50 μg / mL.
[0157] In one embodiment, the concentration of the B27 medium supplement in the fifth culture medium is 1-10% (v / v), preferably 2% (v / v).
[0158] In one embodiment, the concentration of N-acetyl-L-cysteine in the fifth culture medium is 1-100 μM; preferably 10-50 μM, more preferably 30 μM.
[0159] In the present invention, the fourth culture medium and the fifth culture medium are used to induce differentiation of hemogenic endothelial cells into NK cells and activation (maturation and / or expansion) of NK cells.
[0160] In one embodiment, the kit further comprises a third culture medium, which is a basal culture medium comprising at least one, at least two, or at least three of the following: a BMP signaling pathway activator, a growth factor, and a TGFβ / ALK inhibitor.
[0161] In one embodiment, the BMP signaling pathway activator in the third culture medium comprises at least one of BMP2, BMP4, SB4, SJ000291942, SJ000063181, SJ000370178, isoliquiritigenin, diosmetin, apigenin, and biochanin. In a preferred embodiment, the BMP signaling pathway activator in the third culture medium comprises BMP4.
[0162] In one embodiment, the growth factors in the third culture medium include at least one of epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), insulin-like growth factor-I (IGF-1), IGF-II, leukemia inhibitory factor (LIF), nerve growth factor (NGF), oncostatin M (OSM), platelet-derived endothelial cell growth factor (PDECGF), transforming growth factor-α (TGF-α), and vascular endothelial growth factor (VEGF). In a preferred embodiment, the growth factors in the third culture medium include at least one of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF). In a more preferred embodiment, the growth factors in the third culture medium include fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF).
[0163] In one embodiment, the vascular endothelial growth factor comprises at least one of VEGF-A, VEGF-165, VEGF-183, VEGF-110, VEGF-121, VEGF-B, VEGF-C, VEGF-D, and VEGF-E. In a preferred embodiment, the vascular endothelial growth factor comprises VEGF-165.
[0164] In one embodiment, the fibroblast growth factor comprises at least one of acidic fibroblast growth factor and basic fibroblast growth factor. In a preferred embodiment, the fibroblast growth factor comprises basic fibroblast growth factor.
[0165] In one embodiment, the TGFβ / ALK inhibitor in the third culture medium comprises at least one of SB431542, SB-505, A-83-01, GW6604, IN-1130, Ki26894, LY2157299, LY364947 (HTS-466284), LY550410, LY573636, LY580276, NPC-30345, SB-505124, SD-093, Sm16, SM305, SX-007, Antp-Sm2A, and LY2109761. In a preferred embodiment, the TGFβ / ALK inhibitor in the third culture medium comprises SB431542.
[0166] In one embodiment, the concentration of the BMP signaling pathway activator in the third culture medium is 1-50 ng / mL; preferably 1-10 ng / mL; more preferably 5 ng / mL.
[0167] In one embodiment, the concentration of vascular endothelial growth factor in the third culture medium is 1-100 ng / mL; preferably 20-50 ng / mL; more preferably 50 ng / mL.
[0168] In one embodiment, the concentration of fibroblast growth factor in the third culture medium is 1-100 ng / mL; preferably 5-50 ng / mL; more preferably 50 ng / mL.
[0169] In one embodiment, the concentration of the TGFβ / ALK inhibitor in the third culture medium is 1-50 μM; preferably 5-20 μM; more preferably 10 μM.
[0170] In one embodiment, the basal medium of the third culture medium comprises at least one of IMDM (Iscove's Modified Dulbecco's Medium), Eagle's Basal Medium (BME), MEM, DMEM, Ham's F-12, RPMI1640, Fischer's medium, and DMEM / F12. In a preferred embodiment, the basal medium of the third culture medium comprises RPMI1640.
[0171] In one embodiment, the basal medium of the third culture medium comprises at least one, at least two, at least three, or at least four of the following: non-essential amino acids, glutamine, vitamin C, and B27 medium supplement. In a preferred embodiment, the basal medium of the third culture medium comprises non-essential amino acids, glutamine, vitamin C, and B27 medium supplement.
[0172] In one embodiment, the B27 medium supplement is a B27 medium supplement without vitamin A.
[0173] In one embodiment, the concentration of non-essential amino acids in the third culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0174] In one embodiment, the concentration of glutamine in the third culture medium is 0.2-5% (v / v); preferably 0.5-2% (v / v), more preferably 1% (v / v).
[0175] In one embodiment, the concentration of vitamin C in the third culture medium is 10-100 μg / mL; preferably 20-50 μg / mL, more preferably 50 μg / mL.
[0176] In one embodiment, the concentration of the B27 medium supplement in the third culture medium is 1%-10% (v / v), preferably 2% (v / v).
[0177] In the present invention, the third culture medium is used to induce mesodermal cells to differentiate into hemogenic endothelial cells.
[0178] In one embodiment, the kit further comprises a first culture medium, which is a basal culture medium comprising a ROCK inhibitor.
[0179] In one embodiment, the ROCK inhibitor comprises at least one of Blebbistatin, HA-100, Y-27632, HA-1077, KD-025, Y-33075, and Narciclasine. In a preferred embodiment, the ROCK inhibitor comprises Y-27632.
[0180] In one embodiment, the concentration of the ROCK inhibitor in the first culture medium is 1-50 μM; preferably 5 μM-20 μM; more preferably 10 μM.
[0181] In one embodiment, the basal medium of the first culture medium comprises at least one of E8 medium, mTESR medium, StemFit Basic 03, StemFit Basic 04, NutriStem hPSC XF medium, StemMACS iPS Brew medium, Stem-Partner ACF medium, TeSR-AOF medium, and TeSR2 medium. In a preferred embodiment, the basal medium of the first culture medium comprises StemFit Basic 03.
[0182] In the present invention, the first culture medium is used to obtain embryoid bodies.
[0183] In one embodiment, the stem cells described herein are stem cells with multidirectional differentiation potential.
[0184] In one embodiment, the stem cells with multidirectional differentiation potential include at least one of embryonic stem cells, parthenogenetic stem cells, induced pluripotent stem cells, mesenchymal stem cells, adipose-derived stem cells, and umbilical cord blood stem cells. In a preferred embodiment, the stem cells with multidirectional differentiation potential include induced pluripotent stem cells.
[0185] In one embodiment, the stem cells are derived from a mammal; preferably, they are derived from a primate; more preferably, they are derived from a human.
[0186] In one embodiment, the stem cells are commercial human embryonic stem cells (hESCs) (eg, H1, H9) and / or human induced pluripotent stem cells (hiPSCs) (eg, WC50, IMR90).
[0187] In one embodiment, embryonic stem cells are stem cells isolated or obtained from human embryos within 14 days of fertilization that have not undergone in vivo development.
[0188] In a specific embodiment, the kit comprises a first culture medium, a second culture medium, a third culture medium, a fourth culture medium and a fifth culture medium; the first culture medium is StemFit Basic 03 culture medium containing 10 μM Y27632 2HCl; the second culture medium is RPMI1640 culture medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 mg / mL vitamin C, 2% (v / v) B27 culture medium supplement without vitamin A, 20 ng / mL BMP4 and 3 μM CHIR-99021; the third culture medium is RPMI1640 culture medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 mg / mL vitamin C, 2% (v / v) B27 culture medium supplement without vitamin A, 5 ng / mL BMP4, 50 ng / mL VEGF-165, 50 ng / mL bFGF and 10 μM SB431542 RPMI1640 medium; the fourth medium is IMDM medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 mg / mL vitamin C, 2% (v / v) B27 medium supplement without vitamin A, 30 μM N-acetyl-L-cysteine (NAC), 5 ng / mL BMP4, 10 ng / mL VEGF-165, 20 ng / mL SCF, 5 ng / mL IL3, 10 ng / mL IL15, 20 ng / mL IL7, and 10 ng / mL FLT3L; the fifth medium is IMDM medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 mg / mL vitamin C, 2% (v / v) B27 medium supplement without vitamin A, 30 μM NAC, 5 ng / mL BMP4, 10 ng / mL VEGF, 20 ng / mL SCF, 10 ng / mL IMDM medium containing IL15, 20 ng / mL IL7, 10 ng / mL FLT3L, 1 μM UM171, and 1 μM SR1.
[0189] In a specific embodiment, the kit comprises a first culture medium, a second culture medium, a third culture medium, a fourth culture medium and a fifth culture medium; the first culture medium is StemFit Basic03 culture medium containing 10 μM Y27632 or Y27632 2HCl; the second culture medium is RPMI1640 culture medium containing 1% non-essential amino acids, 1% glutamine, 50 mg / mL vitamin C, 2% (v / v) B27 culture medium supplement without vitamin A, 20 ng / mL BMP4 and 3 μM CHIR-99021; the third culture medium is RPMI1640 culture medium containing 1% non-essential amino acids, 1% glutamine, 50 mg / mL vitamin C, 2% (v / v) B27 culture medium supplement without vitamin A, 5 ng / mL BMP4, 50 ng / mL VEGF, 50 ng / mL bFGF and 10 μM SB431542 RPMI1640 medium; the fourth medium is IMDM medium containing 1% non-essential amino acids, 1% glutamine, 50 mg / mL vitamin C, 2% (v / v) B27 medium supplement without vitamin A, 5 ng / mL BMP4, 10 ng / mL VEGF, 20 ng / mL SCF, 5 ng / mL IL3, 10 ng / mL IL15, 20 ng / mL IL7, 10 ng / mL FLT3L; the fifth medium is IMDM medium containing 1% non-essential amino acids, 1% glutamine, 50 mg / mL vitamin C, 2% (v / v) B27 medium supplement without vitamin A, 5 ng / mL BMP4, 10 ng / mL VEGF, 20 ng / mL SCF, 10 ng / mL IL15, 20 ng / mL IL7, 10 ng / mL FLT3L, 1 μM UM171, 1 μM SR1, 30 μM NAC-containing IMDM medium.
[0190] In a second aspect, the present invention provides the use of the kit of the present invention in preparing embryoid bodies, preparing mesodermal cells, preparing hemogenic endothelial cells, preparing natural killer (NK) cells, preparing products for inducing stem cells to differentiate into embryoid bodies, preparing products for inducing stem cells to differentiate into mesodermal cells, preparing products for inducing stem cells to differentiate into hemogenic endothelial cells, and preparing products for inducing stem cells to differentiate into NK cells.
[0191] In one embodiment, the stem cells described herein are stem cells with multidirectional differentiation potential.
[0192] In one embodiment, the stem cells with multidirectional differentiation potential include at least one of embryonic stem cells, parthenogenetic stem cells, induced pluripotent stem cells, mesenchymal stem cells, adipose-derived stem cells, and umbilical cord blood stem cells. In a preferred embodiment, the stem cells with multidirectional differentiation potential include induced pluripotent stem cells.
[0193] In one embodiment, the stem cells are derived from a mammal; preferably, they are derived from a primate; more preferably, they are derived from a human.
[0194] In one embodiment, the stem cells are commercial human embryonic stem cells (hESCs) (eg, H1, H9) and / or human induced pluripotent stem cells (hiPSCs) (eg, WC50, IMR90).
[0195] In one embodiment, human embryonic stem cells are stem cells isolated or obtained from a human embryo within 14 days of fertilization that has not undergone in vivo development.
[0196] Method for inducing stem cells to differentiate into natural killer cells
[0197] In a third aspect, the present invention provides a method for inducing stem cells to differentiate into natural killer cells, the method comprising the steps of using the kit of the first aspect of the present invention.
[0198] In one embodiment, the method comprises:
[0199] Step (1) culturing stem cells to obtain embryoid bodies;
[0200] Step (2) performing mesodermal differentiation culture on the embryoid bodies to obtain mesodermal cells;
[0201] Step (3) differentiating and culturing the mesoderm cells into hemogenic endothelial cells to obtain hemogenic endothelial cells;
[0202] Step (4) The hemogenic endothelial cells are placed in the fourth culture medium and the fifth culture medium of the kit of the first aspect of the present invention and cultured to obtain NK cells.
[0203] In one embodiment, the culturing in step (1) is performed in the first culture medium of the kit of the first aspect of the present invention.
[0204] In one embodiment, the culturing in step (2) is performed in the second culture medium of the kit of the first aspect of the present invention.
[0205] In one embodiment, the culturing in step (3) is performed in the third culture medium of the kit of the first aspect of the present invention.
[0206] In one embodiment, the culturing time in step (1) is 12-36 h, preferably 20-28 h, and more preferably 20-24 h.
[0207] In one embodiment, the culturing time in step (2) is 24-72 h, preferably 36-60 h, and more preferably 42-48 h.
[0208] In one embodiment, the culturing time in step (3) is 48-144 h, preferably 72-120 h, and more preferably 90-96 h.
[0209] In one embodiment, in step (4), culturing the hemogenic endothelial cells in the fourth culture medium and the fifth culture medium of the kit of the first aspect of the present invention is culturing the hemogenic endothelial cells in the fourth culture medium and the fifth culture medium of the kit of the first aspect of the present invention in sequence.
[0210] In one embodiment, the hemogenic endothelial cells are cultured in the fourth culture medium for 96-192 hours, preferably 120-192 hours, and more preferably 144-168 hours.
[0211] In one embodiment, the hemogenic endothelial cells are cultured in the fifth culture medium for 144-432 hours, preferably 216-360 hours, and more preferably 312-336 hours.
[0212] In one embodiment, the hemogenic endothelial cells are maintained in the fifth culture medium with a culture medium change every 5-7 days.
[0213] In one embodiment, the culture conditions are 35-38° C. and 4-6% CO 2 .
[0214] In one embodiment, the culture in steps (1), (2) and (3) is suspension culture.
[0215] In one embodiment, the culturing in steps (1), (2), and (3) is performed in a low attachment plate.
[0216] In one embodiment, the culture in step (4) is adherent culture.
[0217] In one embodiment, the culturing in step (4) is performed in a normal adherent well plate.
[0218] In one embodiment, the stem cells described herein are stem cells with multidirectional differentiation potential.
[0219] In one embodiment, the stem cells with multidirectional differentiation potential include at least one of embryonic stem cells, parthenogenetic stem cells, induced pluripotent stem cells, mesenchymal stem cells, adipose-derived stem cells, and umbilical cord blood stem cells. In a preferred embodiment, the stem cells with multidirectional differentiation potential include induced pluripotent stem cells.
[0220] In one embodiment, the stem cells are derived from a mammal; preferably, they are derived from a primate; more preferably, they are derived from a human.
[0221] In one embodiment, the stem cells are commercial human embryonic stem cells (hESCs) (eg, H1, H9) and / or human induced pluripotent stem cells (hiPSCs) (eg, WC50, IMR90).
[0222] In one embodiment, human embryonic stem cells are stem cells isolated or obtained from a human embryo within 14 days of fertilization that has not undergone in vivo development.
[0223] NK cells
[0224] In a fourth aspect, the present invention provides a natural killer (NK) cell, which is prepared by the kit of the first aspect of the present invention and / or the method of the third aspect of the present invention.
[0225] In one embodiment, the NK cells have CD45 + CD56 + The cell content is 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, or 96% or more; preferably 96% or more; more preferably 96.72%.
[0226] In one embodiment, the NK cells have CD45 + CD3 - The cell content is 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, or 98% or more; preferably 98% or more; more preferably 98.87%.
[0227] In one embodiment, the NK cells have CD56 + CD3 - The cell content is 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, or 97% or more; preferably 97% or more; more preferably 97.12%.
[0228] In one embodiment, the NK cells have CD56 + CD94 + The cell content is 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 51% or more, 52% or more, or 53% or more; preferably 53% or more; more preferably 53.45%.
[0229] In one embodiment, the NK cells have CD45 + CD94 +The cell content is 30% or more, 35% or more, 40% or more, 45% or more, 46% or more, or 47% or more; preferably 47% or more; more preferably 47.90%.
[0230] In one embodiment, the NK cells have CD3 - CD16 - The cell content is 90% or more, 95% or more, or 96% or more; preferably 96% or more; more preferably 96.47%.
[0231] In one embodiment, the NK cells have CD3 - CD45 + CD56 + The cell content is 80% or more, 85% or more, or 90% or more; preferably 90% or more; more preferably 90.64%.
[0232] In one embodiment, the NK cells have CD3 - Nkp46 + The cell content is 60% or more, 65% or more, or 70% or more; preferably 70% or more; more preferably 73.96%.
[0233] In one embodiment, the NK cells have CD3 - CD56 + Nkp44 + The cell content is 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, or 97% or more; preferably 93% or more; more preferably 93.35%.
[0234] In one embodiment, the NK cells have CD3 - CD56 + Nkp30 + The cell content is 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, or 97% or more; preferably 85% or more; more preferably 87.96%.
[0235] In one embodiment, the NK cells have CD3 - CD56 + Nkp44 + Nkp30 + The cell content is 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, or 97% or more; preferably 85% or more; more preferably 85.77%.
[0236] In one embodiment, the NK cells comprise a population of NK cells.
[0237] Pharmaceutical composition
[0238] In a fifth aspect, the present invention provides a pharmaceutical composition comprising the NK cells of the fourth aspect of the present invention.
[0239] In one embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0240] In one embodiment, the pharmaceutical composition is a liquid preparation.
[0241] In one embodiment, the pharmaceutical composition is an intravenous injection agent.
[0242] In one embodiment, the pharmaceutically acceptable carrier includes, but is not limited to, saline, buffer, glucose, water, DMSO, and combinations thereof.
[0243] In one embodiment, the concentration of NK cells in the pharmaceutical composition is 1×10 3 -1×10 7 / μL; preferably 1×10 4 -1×10 6 / μL; more preferably 1×10 5 -9.9×10 5 pcs / μL.
[0244] In one embodiment, the pharmaceutical composition further comprises an anti-tumor drug.
[0245] In one embodiment, the anti-tumor drug comprises at least one of camptothecin, temozolomide, PARP inhibitors, ATR inhibitors, CDK4 / 6 inhibitors, cyclophosphamide, doxorubicin, cisplatin, and paclitaxel; preferably, the drug comprises temozolomide.
[0246] In one embodiment, the NK cells and the anti-tumor drug are mixed or exist independently.
[0247] In one embodiment, the tumor comprises at least one of a blood tumor and a solid tumor; preferably, the tumor comprises at least one of non-small cell lung cancer, small cell lung cancer, colorectal cancer, melanoma, breast cancer, esophageal cancer, gastric cancer, bladder cancer, endometrial cancer, head and neck cancer, cervical cancer, liver cancer, kidney cancer, and glioma; more preferably, the tumor comprises cervical cancer and glioma.
[0248] Drug combinations
[0249] In a seventh aspect, the present invention provides a pharmaceutical combination for treating glioblastoma, the pharmaceutical combination comprising an active ingredient, the active ingredient comprising natural killer (NK) cells and a chemotherapeutic agent, wherein the chemotherapeutic agent comprises temozolomide.
[0250] As used herein, the term "active ingredient" refers to any substance or mixture of substances in a pharmaceutical composition that has pharmacological activity in the diagnosis, treatment, symptom relief, relapse prevention or prevention of disease, and can act directly or indirectly.
[0251] In one embodiment, the glioblastoma is resistant to TMZ.
[0252] In one embodiment, the glioblastoma is resistant to TMZ, and TMZ induces upregulation of expression of one or more immune ligands selected from CD112, CD155, CD54, CD70, B7-H6, CD48, PD-L1, and CD1d in the glioblastoma.
[0253] In one embodiment, the NK cells are unmodified NK cells.
[0254] As used herein, the term "unmodified" means that no genetic modification has been performed by intentionally adding exogenous genetic material such as DNA or RNA in the form of inserted genes to the total genetic material of the cell or editing the genes (directed modification). For example, the term "unmodified" means that no genetic modification has been intentionally performed that results in the insertion or deletion of DNA fragments, or the deletion or substitution of DNA bases.
[0255] In one embodiment, NK cells include, but are not limited to, NK-92 cells, peripheral blood or umbilical cord blood-derived NK cells, NK cells derived from induced pluripotent stem cells (iPSCs) or embryonic stem cells.
[0256] In one embodiment, the embryonic stem cells are commercial human embryonic stem cells (hESCs) (eg, H1, H9).
[0257] In one embodiment, embryonic stem cells are stem cells isolated or obtained from human embryos within 14 days of fertilization that have not undergone in vivo development.
[0258] In one embodiment, the induced pluripotent stem cells (iPSCs) are human induced pluripotent stem cells (hiPSCs) (eg, WC50, IMR90).
[0259] In one embodiment, the NK cells are NK cells derived from induced pluripotent stem cells (iPSCs).
[0260] In one embodiment, the NK cells are unmodified NK cells derived from induced pluripotent stem cells.
[0261] In one embodiment, NK cells derived from induced pluripotent stem cells are prepared by the kit of the first aspect of the present invention or the method of the third aspect of the present invention.
[0262] In one embodiment, the drug combination further comprises other chemotherapeutic agents. Other chemotherapeutic agents include, but are not limited to, anticancer agents, metabolic antagonists, DNA demethylating agents, antitumor agents derived from plants, alkylating agents, antimetabolites, anticancer antibiotics, topoisomerase inhibitors, mitotic inhibitors, differentiation agents, and hormone therapy agents. For example, antitumor agents (e.g., actinomycin D) D), vincristine, vinblastine, alkylating agents, platinum compounds, antimetabolites, and nucleoside analogs such as methotrexate and purine and pyrimidine analogs), antineoplastic agents (e.g., vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate, and streptozotocin), antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, and 5-fluorouracil dacarbazine), alkylating agents (e.g., mechlorethamine, thiotepa
[0015] Examples of the present invention include thiotepa, chlorambucil, razethromycin (CC-1065), melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP, cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), antimitotic agents (e.g., vincristine, vinblastine, paclitaxel, and maytansines). In one embodiment, the other chemotherapeutic agents are selected from anticancer agents, metabolic antagonists, DNA demethylating agents, plant-derived antitumor agents, alkylating agents, antimetabolites, anticancer antibiotics, topoisomerase inhibitors, mitotic inhibitors, differentiating agents, and hormone therapeutic agents. These other chemotherapeutic agents may further include, but are not limited to, carmustine, lomustine, vorinostat, mebendazole, imatinib mesylate, AG119, or any therapeutic derivatives thereof.
[0263] In one embodiment, the additional chemotherapeutic agent is selected from carmustine, lomustine, vorinostat, mebendazole, imatinib mesylate, AG119, or any therapeutic derivative thereof.
[0264] In one embodiment, the active ingredient does not comprise trimetrexate.
[0265] In one embodiment, the active ingredient does not comprise an immune checkpoint inhibitor.
[0266] In one embodiment, the chemotherapeutic agent is only temozolomide.
[0267] In one embodiment, the active ingredients consist of natural killer cells and a chemotherapeutic agent.
[0268] In one embodiment, the active ingredients consist of natural killer cells and temozolomide.
[0269] In one embodiment, the active ingredients are NK-92 cells and temozolomide, peripheral blood-derived or umbilical cord blood-derived NK cells and temozolomide, induced pluripotent stem cell (iPSC)-derived NK cells and temozolomide, or embryonic stem cell-derived NK cells and temozolomide.
[0270] In one embodiment, the active ingredients consist of NK cells derived from induced pluripotent stem cells and temozolomide.
[0271] In one embodiment, the active ingredients consist of unmodified NK cells derived from induced pluripotent stem cells and temozolomide.
[0272] In one embodiment, the active ingredients consist of NK cells derived from induced pluripotent stem cells and temozolomide, and the NK cells derived from induced pluripotent stem cells are prepared by the kit of the first aspect of the present invention.
[0273] In one embodiment, the active ingredients consist of NK cells derived from induced pluripotent stem cells and temozolomide, and the NK cells derived from induced pluripotent stem cells are prepared by the method for inducing stem cell differentiation into natural killer cells according to the third aspect of the present invention.
[0274] In one embodiment, the active ingredients consist of unmodified NK cells derived from induced pluripotent stem cells and temozolomide, and the NK cells derived from induced pluripotent stem cells are prepared by the kit of the first aspect of the present invention.
[0275] In one embodiment, the active ingredient consists of unmodified NK cells derived from induced pluripotent stem cells and temozolomide, and the NK cells derived from induced pluripotent stem cells are prepared by the method for inducing stem cell differentiation into natural killer cells according to the third aspect of the present invention.
[0276] In one embodiment, the drug combination is for treating glioblastoma, wherein the glioblastoma is resistant to TMZ, wherein the drug combination comprises an active ingredient consisting of NK cells derived from induced pluripotent stem cells and temozolomide.
[0277] In one embodiment, the drug combination is for treating glioblastoma, wherein the glioblastoma is resistant to TMZ, wherein the drug combination comprises an active ingredient consisting of unmodified NK cells derived from induced pluripotent stem cells and temozolomide.
[0278] In one embodiment, the active ingredients of the pharmaceutical combination may be administered simultaneously or separately (eg, sequentially).
[0279] In one embodiment, the pharmaceutical combination is a kit.
[0280] In a tenth aspect, the present invention provides a kit comprising natural killer cells and a chemotherapeutic agent as defined in the seventh aspect of the present invention, or the drug combination of the seventh aspect, and instructions for use. The kit may further comprise a suitable container. In certain embodiments, the kit further comprises a device for administering the drug. The kit generally includes a label indicating the intended use and / or instructions for use of the kit contents. The term "label" includes any written or recorded material provided on or with the kit, or otherwise accompanying the kit.
[0281] Methods for treating glioblastoma
[0282] In an eleventh aspect, the present invention further provides a method for treating glioblastoma in a subject in need thereof, comprising the following steps:
[0283] administering natural killer (NK) cells to the subject; and
[0284] administering a chemotherapeutic agent to the subject,
[0285] Among them, chemotherapeutic agents include temozolomide (TMZ).
[0286] In one embodiment, the chemotherapeutic agent is administered prior to administering NK cells to the subject, after administering NK cells to the subject, or concurrently with administering NK cells to the subject, or any combination thereof.
[0287] In one embodiment, the glioblastoma is resistant to TMZ.
[0288] In one embodiment, the glioblastoma is resistant to TMZ, and TMZ induces upregulation of expression of one or more immune ligands selected from CD112, CD155, CD54, CD70, B7-H6, CD48, PD-L1, and CD1d in the glioblastoma.
[0289] In one embodiment, the NK cells are unmodified NK cells.
[0290] In one embodiment, NK cells include but are not limited to NK-92 cells, peripheral blood-derived or umbilical cord blood-derived NK cells, NK cells derived from induced pluripotent stem cells (iPSCs) or embryonic stem cells.
[0291] In one embodiment, the embryonic stem cells are commercial human embryonic stem cells (hESCs) (eg, H1, H9).
[0292] In one embodiment, embryonic stem cells are stem cells isolated or obtained from human embryos within 14 days of fertilization that have not undergone in vivo development.
[0293] In one embodiment, the induced pluripotent stem cells (iPSCs) are human induced pluripotent stem cells (hiPSCs) (eg, WC50, IMR90).
[0294] In one embodiment, the NK cells are NK cells derived from induced pluripotent stem cells (iPSCs).
[0295] In one embodiment, the NK cells are unmodified NK cells derived from induced pluripotent stem cells.
[0296] In one embodiment, NK cells derived from induced pluripotent stem cells are prepared by the kit of the first aspect of the present invention.
[0297] In one embodiment, NK cells derived from induced pluripotent stem cells are prepared by the method for inducing stem cell differentiation into natural killer cells according to the third aspect of the present invention.
[0298] In one embodiment, the method further comprises administering to the subject other chemotherapeutic agents. Other chemotherapeutic agents include, but are not limited to, anticancer agents, metabolic antagonists, DNA demethylating agents, antitumor agents derived from plants, alkylating agents, antimetabolites, anticancer antibiotics, topoisomerase inhibitors, mitotic inhibitors, differentiation agents, and hormone therapeutic agents. For example, antitumor agents (e.g., actinomycin D) D), vincristine, vinblastine, alkylating agents, platinum compounds, antimetabolites, and nucleoside analogs such as methotrexate and purine and pyrimidine analogs), antineoplastic agents (e.g., vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate, and streptozotocin), antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, and 5-fluorouracil dacarbazine), alkylating agents (e.g., mechlorethamine, thiotepa
[0015] Examples of the present invention include thiotepa, chlorambucil, razethromycin (CC-1065), melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP, cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), antimitotic agents (e.g., vincristine, vinblastine, paclitaxel, and maytansines). In one embodiment, other chemotherapeutic agents are selected from anticancer agents, metabolic antagonists, DNA demethylating agents, antitumor agents derived from plants, alkylating agents, antimetabolites, anticancer antibiotics, topoisomerase inhibitors, mitotic inhibitors, differentiating agents, hormone therapy agents. These other chemotherapeutic agents may further include, but are not limited to, carmustine, lomustine, vorinostat, mebendazole, imatinib mesylate, AG119, or any therapeutic derivatives thereof.
[0299] In one embodiment, the additional chemotherapeutic agent is selected from carmustine, lomustine, vorinostat, mebendazole, imatinib mesylate, AG119, or any therapeutic derivative thereof.
[0300] In one embodiment, the other chemotherapeutic agent is administered before the subject is administered NK cells or temozolomide (TMZ), after the subject is administered NK cells or temozolomide (TMZ), or simultaneously with the subject being administered NK cells or temozolomide (TMZ), or any combination thereof.
[0301] In one embodiment, the method does not comprise administering trimetrexate to the subject.
[0302] In one embodiment, the method does not comprise administering an immune checkpoint inhibitor to the subject.
[0303] In one embodiment, the chemotherapeutic agent is temozolomide (TMZ).
[0304] In one embodiment, the method comprises the following steps:
[0305] administering natural killer (NK) cells to the subject; and
[0306] The subject is administered a chemotherapeutic agent, wherein the chemotherapeutic agent is administered before the subject is administered with NK cells, after the subject is administered with NK cells, or simultaneously with the subject is administered with NK cells, or any combination thereof, wherein the chemotherapeutic agent is temozolomide.
[0307] In one embodiment, the method comprises the following steps:
[0308] administering to the subject NK cells derived from induced pluripotent stem cells; and
[0309] The subject is treated with a chemotherapeutic agent, wherein the chemotherapeutic agent is administered before the subject is treated with NK cells derived from induced pluripotent stem cells, after the subject is treated with NK cells derived from induced pluripotent stem cells, or simultaneously with the subject being treated with NK cells derived from induced pluripotent stem cells, or any combination thereof, wherein the chemotherapeutic agent is temozolomide.
[0310] In one embodiment, a method for treating glioblastoma in a subject in need thereof comprises the steps of:
[0311] administering to the subject NK cells derived from induced pluripotent stem cells; and
[0312] administering a chemotherapeutic agent to the subject, wherein the chemotherapeutic agent is administered before administering the NK cells derived from induced pluripotent stem cells to the subject, after administering the NK cells derived from induced pluripotent stem cells to the subject, or concurrently with administering the NK cells derived from induced pluripotent stem cells to the subject, or any combination thereof,
[0313] Among them, the chemotherapy agent is temozolomide (TMZ),
[0314] Among them, glioblastoma is resistant to TMZ.
[0315] In one embodiment, a method for treating glioblastoma in a subject in need thereof comprises the steps of:
[0316] administering to the subject unmodified NK cells derived from induced pluripotent stem cells; and
[0317] administering a chemotherapeutic agent to the subject, wherein the chemotherapeutic agent is administered before administering unmodified NK cells derived from induced pluripotent stem cells to the subject, after administering unmodified NK cells derived from induced pluripotent stem cells to the subject, or concurrently with administering unmodified NK cells derived from induced pluripotent stem cells to the subject, or any combination thereof,
[0318] Among them, the chemotherapy agent is temozolomide (TMZ),
[0319] Among them, glioblastoma is resistant to TMZ.
[0320] In one embodiment, a method for treating glioblastoma in a subject in need thereof comprises the steps of:
[0321] administering to the subject NK cells derived from induced pluripotent stem cells; and
[0322] administering a chemotherapeutic agent to the subject, wherein the chemotherapeutic agent is administered before administering the NK cells derived from induced pluripotent stem cells to the subject, after administering the NK cells derived from induced pluripotent stem cells to the subject, or concurrently with administering the NK cells derived from induced pluripotent stem cells to the subject, or any combination thereof,
[0323] Among them, the chemotherapy agent is temozolomide (TMZ),
[0324] Among them, glioblastoma is resistant to TMZ.
[0325] Wherein, NK cells derived from induced pluripotent stem cells are prepared by the kit of the first aspect of the present invention.
[0326] In one embodiment, a method for treating glioblastoma in a subject in need thereof comprises the steps of:
[0327] administering to the subject NK cells derived from induced pluripotent stem cells; and
[0328] administering a chemotherapeutic agent to the subject, wherein the chemotherapeutic agent is administered before administering the NK cells derived from induced pluripotent stem cells to the subject, after administering the NK cells derived from induced pluripotent stem cells to the subject, or concurrently with administering the NK cells derived from induced pluripotent stem cells to the subject, or any combination thereof,
[0329] Among them, the chemotherapy agent is temozolomide (TMZ),
[0330] Among them, glioblastoma is resistant to TMZ.
[0331] The NK cells derived from induced pluripotent stem cells are prepared by the method for inducing stem cells to differentiate into natural killer cells according to the third aspect of the present invention.
[0332] In one embodiment, the subject is administered the chemotherapeutic agent 8 to 72 hours before, 8 to 72 hours after, or both before and 8 to 72 hours after the NK cells are administered to the subject.
[0333] In one embodiment, the subject is treated with a chemotherapeutic agent 8, 16, 24, 32, 40, 48, 56, 64, 72 hours before, 8, 16, 24, 32, 40, 48, 56, 64, 72 hours after, or both before and after administration of the NK cells.
[0334] In one embodiment, temozolomide is administered to the subject 8, 16, 24, 32, 40, 48, 56, 64, 72 hours before administration of NK cells to the subject, 8, 16, 24, 32, 40, 48, 56, 64, 72 hours after administration of NK cells to the subject, or both before administration of NK cells to the subject and 8, 16, 24, 32, 40, 48, 56, 64, 72 hours after administration of NK cells to the subject.
[0335] In one embodiment, temozolomide treatment is administered to the subject 8, 16, 24, 32, 40, 48, 56, 64, 72 hours before, 8, 16, 24, 32, 40, 48, 56, 64, 72 hours after, or both before and after administration of NK cells derived from induced pluripotent stem cells to the subject.
[0336] Applications, uses and treatments
[0337] In a sixth aspect, the present invention provides use of the NK cell of the fourth aspect of the present invention or the pharmaceutical composition of the fifth aspect of the present invention in the preparation of a drug for preventing and / or treating tumors.
[0338] In a ninth aspect, the present invention provides a method for treating tumors, comprising: administering the NK cells of the fourth aspect of the present invention or administering the pharmaceutical composition of the fifth aspect of the present invention to a subject.
[0339] In one embodiment, the subject is a mammal, preferably a primate, more preferably a human.
[0340] In one embodiment, the site of administration is a vein of the subject.
[0341] In one embodiment, the tumor comprises at least one of a blood tumor and a solid tumor; preferably, the tumor comprises at least one of non-small cell lung cancer, small cell lung cancer, colorectal cancer, melanoma, breast cancer, esophageal cancer, gastric cancer, bladder cancer, endometrial cancer, head and neck cancer, cervical cancer, liver cancer, kidney cancer, and glioma; more preferably, the tumor comprises cervical cancer and glioma.
[0342] In an eighth aspect, the present invention provides use of the natural killer (NK) cells and chemotherapeutic agents defined in the seventh aspect, the drug combination of the seventh aspect, or the kit of the tenth aspect in the preparation of a drug for treating glioblastoma.
[0343] In one embodiment, the glioblastoma is resistant to TMZ.
[0344] In one embodiment, the glioblastoma is resistant to TMZ, and TMZ induces upregulation of expression of one or more immune ligands selected from CD112, CD155, CD54, CD70, B7-H6, CD48, PD-L1, and CD1d in the glioblastoma.
[0345] In one embodiment, the chemotherapeutic agent is administered before, after, or simultaneously with the administration of NK cells.
[0346] In one embodiment, the chemotherapeutic agent is administered 8 to 72 hours before, 8 to 72 hours after, or both before and 8 to 72 hours after administration of the NK cells.
[0347] In a twelfth aspect, the present invention provides natural killer (NK) cells and a chemotherapeutic agent as defined in the seventh aspect of the present invention, the pharmaceutical combination of the seventh aspect of the present invention, or the kit of the tenth aspect of the present invention for treating glioblastoma.
[0348] In one embodiment, the glioblastoma is resistant to TMZ.
[0349] In one embodiment, the glioblastoma is resistant to TMZ, and TMZ induces upregulation of expression of one or more immune ligands selected from CD112, CD155, CD54, CD70, B7-H6, CD48, PD-L1, and CD1d in the glioblastoma.
[0350] In one embodiment, the method of the present invention for treating glioblastoma in a subject in need thereof comprises the following steps:
[0351] administering to a subject a therapeutically effective amount of NK cells as defined in the seventh aspect of the present invention; and
[0352] The subject is administered a therapeutically effective amount of a chemotherapeutic agent as defined in the seventh aspect of the invention, wherein the chemotherapeutic agent is administered before the subject is administered with NK cells, after the subject is administered with NK cells, or simultaneously with the subject being administered with NK cells, or any combination thereof.
[0353] As used herein, the term "treat" means improving or reversing at least one measurable physical parameter associated with cancer (e.g., glioblastoma or glioblastoma resistant to TMZ), which is not necessarily discernible in the subject, but can be discernible in the subject. The term "treat" can also refer to causing regression, preventing progression, or at least slowing the progression of a disease, disorder, or condition. In a specific embodiment, "treat" refers to alleviating, preventing the development or onset of one or more symptoms associated with a disease, disorder, or condition (such as a tumor or more preferably cancer, e.g., glioblastoma or glioblastoma resistant to TMZ), or reducing the duration. In a specific embodiment, "treat" refers to preventing the recurrence of a disease, disorder, or condition. In a specific embodiment, "treat" refers to increasing the survival of a subject suffering from a disease, disorder, or condition. In a specific embodiment, "treat" refers to eliminating a disease, disorder, or condition in a subject.
[0354] The term "therapeutically effective amount" refers to an amount of an agent (e.g., a drug, a drug combination, or a reagent in a kit) sufficient to prevent or inhibit the occurrence of a disease or symptom and / or slow, alleviate, or delay the development or severity of a disease or symptom. The therapeutically effective amount is affected by factors including, but not limited to, the rate of development and severity of the disease or symptom, the age, sex, weight, and physical condition of the subject, the duration of treatment, and the specific route of administration. The therapeutically effective amount can be administered in one or more doses. The therapeutically effective amount can be achieved by continuous or intermittent administration.
[0355] According to certain embodiments, a therapeutically effective amount may refer to a therapeutic amount sufficient to achieve one, two, three, four or more of the following effects: (i) reduce or ameliorate the severity of the disease, disorder or condition being treated, or the symptoms associated therewith; (ii) reduce the duration of the disease, disorder or condition being treated, or the symptoms associated therewith; (iii) prevent the progression of the disease, disorder or condition being treated, or the symptoms associated therewith; (iv) cause the regression of the disease, disorder or condition being treated, or the symptoms associated therewith; (v) prevent the development or onset of the disease, disorder or condition being treated, or the symptoms associated therewith. (vi) prevent recurrence of the disease, disorder or condition being treated, or symptoms associated therewith; (vii) reduce hospitalization of a subject suffering from the disease, disorder or condition being treated, or symptoms associated therewith; (viii) reduce the length of hospital stay of a subject suffering from the disease, disorder or condition being treated, or symptoms associated therewith; (ix) increase survival of a subject suffering from the disease, disorder or condition being treated, or symptoms associated therewith; (xi) inhibit or reduce the disease, disorder or condition being treated, or symptoms associated therewith, in a subject; and / or (xii) enhance or improve the prophylactic or therapeutic effect of another therapy.
[0356] In one embodiment, the natural killer (NK) cells and chemotherapeutic agents defined in the seventh aspect of the present invention, the drug combination of the seventh aspect of the present invention, the method of the eleventh aspect of the present invention, the kit of the tenth aspect of the present invention, or the drug defined in the eighth aspect of the present invention can also be used to treat sensitive GBM that gradually develops resistance to drugs, develops various strategies to escape the effects of TMZ, and finally transforms into drug-resistant GBM.
[0357] The NK cells of the present application and / or the drug combination of the present application can be administered in any physiologically acceptable carrier. The cell population comprising the NK cells of the present application can include a purified cell population. Those skilled in the art can easily determine the cells in the cell population using various well-known methods, and its purity range can be from about 50% to about 55%, from about 55% to about 60%, from about 60% to about 65%, from about 65% to about 70%, from about 70% to about 75%, from about 75% to about 80%, from about 80% to about 85%, from about 85% to about 90%, from about 90% to about 95% or from about 95% to about 100%. Those skilled in the art can easily adjust dosage, for example, and purity reduction may require dosage increase.
[0358] The NK cells of the present application can be administered at a dose based on cells / kilogram (cells / kg) of subject body weight, and NK cells and / or a drug combination comprising NK cells can be administered to a subject. Generally, the cell dose is about 10 4 to about 10 10cells / kg body weight, for example, about 10 5 to about 10 9 , about 10 5 to about 10 8 , about 10 5 to about 10 7 or about 10 5 to about 10 6 , depending on the route and site of administration. Exemplary dosage ranges include, but are not limited to, 1×10 4 -1×10 8 , 2×10 4 -1×10 8 , 3×10 4 -1×10 8 , 4×10 4 -1×10 8 , 5×10 4 -6×10 8 , 7×10 4 -1×10 8 , 8×10 4 -1×10 8 , 9×10 4 -1×10 8 , 1×10 5 -1×10 8 , 1×10 5 -9×10 7 , 1×10 5 -8×10 7 , 1×10 5 -7×10 7 , 1×10 5 -6×10 7 , 1×10 5 -5×10 7 , 1×10 5 -4×10 7 , 1×10 5 -4×10 7 , 1×10 5 -3×10 7 , 1×10 5 -2×10 7 , 1×10 5 -1×10 7 , 1×10 5 -9×10 6 , 1×10 5 -8×10 6 , 1×10 5 -7×10 6 , 1×10 5 -6×10 6、1×10 5 -5×10 6 、1×10 5 -4×10 6 、1×10 5 -4×10 6 、1×10 5 -3×10 6 、1×10 5 -2×10 6 、1×10 5 -1×10 6 、2×10 5 -9×10 7 、2×10 5 -8×10 7 、2×10 5 -7×10 7 、2×10 5 -6×10 7 、2×10 5 -5×10 7 、2×10 5 -4×10 7 、2×10 5 -4×10 7 、2×10 5 -3×10 7 、2×10 5 -2×10 7 、2×10 5 -1×10 7 、2×10 5 -9×10 6 、2×10 5 -8×10 6 、2×10 5 -7×10 6 、2×10 5 -6×10 6 、2×10 5 -5×10 6 、2×10 5 -4×10 6 、2×10 5 -4×10 6 、2×10 5 -3×10 6 、2×10 5 -2×10 6 、2×10 5 -1×10 6 、3×10 5 -3×10 6Cells / kg, etc. In addition, the dose can be adjusted to take into account whether a single dose is administered or whether multiple doses are administered. What is considered an effective dose can be accurately determined based on individual factors for each subject.
[0359] As used herein, the term "effector-to-target ratio (E:T)" refers to the ratio of effector cells to target cells. In some embodiments herein, the E:T ratio refers to the ratio of NK cells to glioblastoma cells used. Exemplary E:T ratio ranges include, but are not limited to, 100:1, 90:1, 85:1, 80:1, 75:1, 70:1, 65:1, 60:1, 55:1, 50:1, 45:1, 40:1, 35:1, 30:1, 25:1, 20:1, 19:1, 18:1, 17:1, 16:1, 15:1, 14:1, 13:1, 1 In some embodiments, the effector-target ratio is 1:1, 1:4, or 1:8. In one embodiment, the effector-target ratio is 1:1.
[0360] The TMZ of the present application can be administered at a dose of mg / kg body weight of the subject, and TMZ and / or a drug combination comprising TMZ can be administered to the subject. Exemplary dosages include, but are not limited to, about 0.01, about 0.05, about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.8, about 1, about 2, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, or about 1000 mg / kg of subject.
[0361] The TMZ of this application can be expressed in mg / m 2The subject is administered TMZ and / or a drug combination comprising TMZ. Exemplary dosages include, but are not limited to, about 0.01, about 0.05, about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.8, about 1, about 2, about 5, about 10, about 15, about 20, about 25, about 30, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, or about 1000 mg / m 2 Subject.
[0362] The amount of TMZ used in the present application can be, for example, 0.001-5000 μM, for example 10-1000 μM, for example 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 650, 700, 750, 800, 850, 900, 950, 1000 μM. Beneficial effects
[0363] The present invention provides a kit for inducing stem cell differentiation into natural killer cells. The kit uses a culture medium with a clear chemical composition, chemical small molecules, and cytokines, and does not involve substances such as serum that are prone to causing unstable factors such as batch differences. In addition, the kit is cheaper than known commercial differentiation culture media and has a shortened differentiation cycle.
[0364] The present invention provides an efficient and clear NK cell differentiation strategy based on the above-mentioned kit, which cultured stem cells to obtain embryoid bodies, then subjected the embryoid bodies to mesoderm differentiation culture to obtain mesodermal cells, then subjected the mesoderm cells to hemogenic endothelial differentiation culture to obtain hemogenic endothelial cells, and finally subjected the hemogenic endothelial cells to NK cell differentiation to obtain NK cells; because the kit uses a culture medium with clear chemical composition, chemical small molecules and cytokines, the entire differentiation process does not involve the influence of serum (human AB serum) and matrix proteins and matrix cells, making the induced differentiation method more standardized and providing a large number of uniform functional NK cells for clinical treatment transformation; at the same time, the EB differentiation method is used in the hemogenic endothelial cell differentiation stage, which shortens the early differentiation cycle and has a high efficiency in obtaining hemogenic endothelial cells, thereby improving the subsequent differentiation quantity, differentiation quality and differentiation purity of NK cells; the CD45 + CD94 + cells and CD56 +CD94 + The cell content is significantly increased, and it has a strong function of secreting IFN-γ and has a good function of killing tumor cells. The obtained NK cells can be combined with the current CAR treatment method to improve the targeting and killing effect of NK cells on tumor cells. What is even more surprising is that the mature NK cells finally prepared by the present invention have an amplification multiple of more than 500 times compared with the initial iPSC cells, and the usual NK cell amplification step is no longer required, which greatly facilitates cell transplantation and related disease treatment. At the same time, this induction method can also be applied to the current universal iPSC, thereby inducing the differentiation of universal NK cells, which are suitable for a variety of patients.
[0365] The NK cells combined with TMZ of the present invention, and their corresponding drug combinations or kits, can exhibit excellent effects, such as, but not limited to: (1) NK cells exhibiting stronger degranulation activity; (2) having stronger tumor cell killing activity against drug-resistant GBM; (3) being able to resist the immunosuppressive effects of drug-resistant GBM; and (4) prolonging survival. In particular, NK cells derived from induced pluripotent stem cells combined with TMZ have the most excellent tumor cell killing activity against drug-resistant GBM.
[0366] Example
[0367] The present invention is further described with reference to the following examples. It should be understood that these examples are intended to be illustrative only and are not intended to limit the present invention. Unless otherwise specified, the following materials and instruments are commercially available or prepared according to methods known in the art. Furthermore, unless otherwise specified, the following experiments were performed according to the manufacturer's instructions or according to methods and procedures known in the art.
[0368] The human induced pluripotent stem cells (iPSCs) used in this example are iPSCs reprogrammed by our company, which were obtained through CTS TM CytoTune TM iPS cells were prepared using the Sendai virus reprogramming kit (Cat. No. A34546) (see the kit instructions for specific methods). The initial cells were human peripheral blood cells.
[0369] In this example, low-attachment 96-well plates were purchased from Corning; BMP4 was purchased from StemImmune LLC, Cat# HST-B4-0100; CHIR-99021 was purchased from selleck; non-essential amino acids were purchased from Gibco, Cat# 11140050; glutamine was purchased from Gibco; vitamin C was purchased from Sigma; and B27 medium supplement without vitamin A was purchased from Gibco.
[0370] Example 1 A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0371] A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells, comprising: a first culture medium, a second culture medium, a third culture medium, a fourth culture medium, and a fifth culture medium;
[0372] The first culture medium is StemFit Basic 03 medium (Company: Ajinomoto, Catalog No.: AK03N) containing 10 μM Y27632·2HCl;
[0373] The second culture medium is a differentiation medium containing 20 ng / mL BMP4 (bone morphogenetic protein 4) and 3 μM CHIR-99021, wherein the differentiation medium is RPMI1640 medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, and 2% (v / v) B27 medium supplement without vitamin A;
[0374] The third culture medium is a differentiation medium containing 5 ng / mL BMP4, 50 ng / mL VEGF-165 (vascular endothelial growth factor), 50 ng / mL bFGF (basic fibroblast growth factor), and 10 μM SB431542, wherein the differentiation medium is RPMI1640 medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, and 2% (v / v) B27 medium supplement without vitamin A;
[0375] The fourth culture medium is a differentiation medium containing 5 ng / mL BMP4, 10 ng / mL VEGF-165, 20 ng / mL SCF (stem cell factor), 5 ng / mL IL3 (multiple colony-stimulating factor, multi-CSF), 10 ng / mL IL15 (interleukin 15), 20 ng / mL IL7 (interleukin 7), and 10 ng / mL FLT3L (Fms-related tyrosine kinase 3 ligand), wherein the differentiation medium is IMDM (Iscove's Modified Dulbecco's Medium) medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, 2% (v / v) B27 medium supplement without vitamin A, and 30 μM N-acetyl-L-cysteine;
[0376] The fifth culture medium is a differentiation medium containing 5 ng / mL BMP4, 10 ng / mL VEGF-165, 20 ng / mL SCF, 10 ng / mL IL15, 20 ng / mL IL7, 10 ng / mL FLT3L, 1 μM UM171 (CAS No.: 1448724-09-1), and 1 μM SR1 (CAS No.: 1227633-49-9), wherein the differentiation medium is IMDM medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, 2% (v / v) B27 medium supplement without vitamin A, and 30 μM N-acetyl-L-cysteine.
[0377] Example 2 A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0378] A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells, comprising the steps of using the kit of Example 1, comprising the following steps (a schematic diagram of differentiation is shown in Figure 1A):
[0379] Step (1) culturing human induced pluripotent stem cells in a low-attachment 96-well plate to obtain embryoid bodies:
[0380] Press 2×10 5 Cells / well iPSCs were seeded into low-attachment six-well plates using the first culture medium and cultured at 37°C, 5% CO2 for one day to obtain embryoid bodies, which was designated as D0;
[0381] Step (2) performing mesodermal differentiation culture on the embryoid bodies to obtain mesodermal cells:
[0382] One day later, the first culture medium was replaced with the second culture medium and cultured at 37°C and 5% CO2 for two days, which was designated as D2 to obtain mesoderm cells (ME cells);
[0383] Step (3) performing hemogenic endothelial differentiation culture on the mesoderm cells to obtain hemogenic endothelial cells:
[0384] Two days later, the second culture medium was replaced with the third culture medium and cultured at 37°C and 5% CO2 for four days to obtain hemogenic endothelial cells (HE cells);
[0385] Step (4) performing NK cell differentiation culture on hemogenic endothelial cells to obtain NK cells:
[0386] After four days, the embryoid bodies (hemogenic endothelial cells obtained after four days of culture in step (3)) in the low-attachment 96-well plate were collected and placed in a 50 mL centrifuge tube. The cells were allowed to settle naturally for 1-2 minutes, and then the supernatant was removed. About 5 mL of supernatant remained in the centrifuge tube. Then 14 mL of the fourth culture medium was added, and the cell balls were gently pipetted to mix. The cells were evenly distributed into three normally adherent 6-well plates and returned to the incubator for culture at 37°C and 5% CO2 for 7 days. The cell morphology after 2 days of culture (iNK-D2, EB adherent D2) is shown in Figure 1B.
[0387] After seven days, gently remove about 1 mL of the supernatant from the six-well plate, then add 3 mL of the fifth culture medium to each well of the six-well plate and return it to the incubator for culture at 37°C and 5% CO2 for 7 days;
[0388] After seven days, 2 mL of the fifth culture medium was added to each well of the six-well plate and the plate was returned to the incubator for culture at 37°C and 5% CO2 for 7 days. The cell morphology of iNK-D20 cells after 6 days of culture is shown in Figure 1C.
[0389] Step (5) collecting differentiated NK cells:
[0390] On the 13th, 16th, and 20th days of NK cell differentiation culture of hemogenic endothelial cells, the supernatant (suspended cells) in the six-well plate was collected into a centrifuge tube and centrifuged at 1500 rpm for 10 minutes. The cells were then resuspended in 5 mL of the fifth culture medium. The cell suspension was then passed through a 70 μm cell sieve to filter the cells. The filtered cell suspension was centrifuged again at 1500 rpm for 5 minutes. The cells were resuspended in 5 mL of the fifth culture medium and AO / PI cell counting was performed. The cell viability and cell number were recorded. Subsequent cell testing and cell freezing experiments were performed as needed.
[0391] Example 3-1 A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0392] A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as that in Example 1, except that the concentration of BMP4 (bone morphogenetic protein 4) in the second culture medium is 2 ng / mL.
[0393] Example 3-2 A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0394] A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as that in Example 1, except that the concentration of BMP4 (bone morphogenetic protein 4) in the second culture medium is 10 ng / mL.
[0395] Example 3-3 A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0396] A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as that in Example 1, except that the concentration of BMP4 (bone morphogenetic protein 4) in the second culture medium is 5 ng / mL.
[0397] Example 4-1 A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0398] A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as that of Example 2, except that the kit of Example 3-1 is used.
[0399] Example 4-2 A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0400] A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as that of Example 2, except that the kit of Example 3-2 is used.
[0401] Example 4-3 A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0402] A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as that of Example 2, except that the kit of Example 3-3 is used.
[0403] Comparative Example 1 A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0404] A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells, comprising: a first culture medium, a second culture medium, a third culture medium, a fourth culture medium, and a fifth culture medium;
[0405] Among them, the first culture medium contains 10 μM Y27632·2HCl Basic 03 medium;
[0406] The second culture medium is a differentiation medium containing 20 ng / mL BMP4 (bone morphogenetic protein 4) and 3 μM CHIR-99021, wherein the differentiation medium is RPMI1640 medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, and 2% (v / v) B27 medium supplement without vitamin A;
[0407] The third culture medium is a differentiation medium containing 5 ng / mL BMP4, 50 ng / mL VEGF-165 (vascular endothelial growth factor), 50 ng / mL bFGF (basic fibroblast growth factor), and 10 μM SB431542, wherein the differentiation medium is RPMI1640 medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, and 2% (v / v) B27 medium supplement without vitamin A;
[0408] The fourth culture medium is a differentiation medium containing 20 ng / mL SCF (stem cell factor), 5 ng / mL IL3 (interleukin 3), 10 ng / mL IL15 (interleukin 15), 10 ng / mL IL7 (interleukin 7), and 10 ng / mL FLT3L (Fms-related tyrosine kinase 3 ligand), wherein the differentiation medium is X-VIVO15 medium (X-VIVO15 medium) containing 20% (v / v) Human AB-FBS (human AB serum);
[0409] The fifth culture medium is a differentiation medium containing 20 ng / mL SCF (stem cell factor), 10 ng / mL IL15 (interleukin 15), 10 ng / mL IL7 (interleukin 7) and 10 ng / mL FLT3L (Fms-related tyrosine kinase 3 ligand), wherein the differentiation medium is X-VIVO15 medium (X-VIVO15 medium) containing 20% (v / v) Human AB-FBS (human AB serum).
[0410] Comparative Example 2 A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0411] A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as Example 2, except that: the kit of Comparative Example 1 is used; and step (5) is performed only on the 20th day of culturing hemogenic endothelial cells for NK cell differentiation, the supernatant (suspended cells) in the six-well plate is collected into a centrifuge tube.
[0412] Comparative Example 3: A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0413] A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells, comprising: a first culture medium, a second culture medium, a third culture medium, a fourth culture medium, and a fifth culture medium;
[0414] Among them, the first culture medium contains 10 μM Y27632·2HCl Basic 03 medium;
[0415] The second culture medium is a differentiation medium containing 20 ng / mL BMP4 (bone morphogenetic protein 4) and 3 μM CHIR-99021, wherein the differentiation medium is RPMI1640 medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, and 2% (v / v) B27 medium supplement without vitamin A;
[0416] The third culture medium is a differentiation medium containing 5 ng / mL BMP4, 50 ng / mL VEGF-165 (vascular endothelial growth factor), 50 ng / mL bFGF (basic fibroblast growth factor), and 10 μM SB431542, wherein the differentiation medium is RPMI1640 medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, and 2% (v / v) B27 medium supplement without vitamin A;
[0417] The fourth culture medium is a differentiation medium containing 20 ng / mL SCF (stem cell factor), 5 ng / mL IL3 (interleukin 3), 10 ng / mL IL15 (interleukin 15), 10 ng / mL IL7 (interleukin 7), 10 ng / mL FLT3L (Fms-related tyrosine kinase 3 ligand), 5 ng / mL sodium selenite, 50 μM ethanolamine, 1 μM β-mercaptoethanol, and 20 μg / mL ascorbic acid. The differentiation medium is DMEM / Ham's F-12 (2:1) (DF-12) medium (DMEM high glucose medium:Ham's F-12 medium = 2:1 (v / v)) containing 20% Human AB-FBS.
[0418] The fifth culture medium is a differentiation medium containing 20 ng / mL SCF (stem cell factor), 5 ng / mL IL3 (interleukin 3), 10 ng / mL IL15 (interleukin 15), 10 ng / mL IL7 (interleukin 7), 10 ng / mL FLT3L (Fms-related tyrosine kinase 3 ligand), 5 ng / mL sodium selenite, 50 μM ethanolamine, 1 μM β-mercaptoethanol, and 20 μg / mL ascorbic acid. The differentiation medium is DMEM / Ham's F-12 (2:1) (DF-12) medium containing 20% Human AB-FBS (human AB serum) (DMEM high glucose medium:Ham's F-12 medium = 2:1 (v / v)).
[0419] Comparative Example 4: A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0420] A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as Example 2, except that: the kit of Comparative Example 3 is used; and step (5) is only performed on the 20th day of culturing hemogenic endothelial cells for NK cell differentiation, and the supernatant (suspended cells) in the six-well plate is collected into a centrifuge tube.
[0421] Comparative Example 5: A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0422] A kit for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as that in Example 1, except that the concentration of BMP4 (bone morphogenetic protein 4) in the second culture medium is 0 ng / mL.
[0423] Comparative Example 6: A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells
[0424] A method for inducing human induced pluripotent stem cells to differentiate into natural killer cells is the same as that of Example 2, except that the kit of Comparative Example 5 is used.
[0425] Effect Example 1
[0426] The NK cells collected on the 13th, 16th, and / or 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2, Example 4-1, Example 4-2, Example 4-3, Comparative Example 2, Comparative Example 4, and Comparative Example 6 were collected into centrifuge tubes, placed in a centrifuge and centrifuged at 1500 rpm for 5 minutes, the supernatant was discarded, and the cells were resuspended with PBS. The cells resuspended in PBS were centrifuged again for 3 minutes at 1500 rpm, the supernatant was removed, and then the cells were resuspended in 100 μL of PBS containing 0.5% bovine serum albumin (BSA). The corresponding volume of antibodies was added according to the antibody instructions (the antibodies are shown in Table 1), and the cells were incubated at room temperature in the dark for 20 minutes. After that, the cells were washed three times with PBS, and then the cells were resuspended with 200 μL of PBS and placed in a flow cytometer for flow cytometry detection. The results are shown in Figures 2, 3, 4, 5, and 6: In the cells collected on the 13th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2, CD45 + CD56 + The cell ratio was 72.18%; in the cells collected on the 16th day of NK cell differentiation culture of hemogenic endothelial cells, CD45 + CD56 + The cell ratio was 89.53%; in the cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells, CD45 + CD56 + The cell ratio was 96.72%, CD45 + CD3 - The cell ratio was 98.87%, CD56 + CD3 - The cell ratio was 97.12%, CD56 + CD94 + The cell ratio was 53.45%, CD45 + CD94 + The cell ratio was 47.90%, CD3 - CD45 + CD56 + The cell ratio was 90.64%, CD3 - CD16 - The cell ratio was 96.47%, CD3 - Nkp46 + The cell ratio was 73.96%, CD3 - CD56 + Nkp44 + The cell ratio was 93.35%, CD3 - CD56 + Nkp30 + The cell ratio was 87.96%, CD3- CD56 + Nkp44 + Nkp30 + The cell ratio was 85.77%; in the cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Comparative Example 2, CD45 + CD56 + The cell ratio was 95.10%, CD45 + CD3 - The cell ratio was 99.24%, CD43 + CD3 - The cell ratio was 97.95%, CD56 + CD94 + The cell ratio was 29.37%, CD45 + CD94 + The cell ratio was 24.44%; in the cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Comparative Example 4, CD45 + CD56 + The cell ratio was 92.17%, CD45 + CD3 - The cell ratio was 99.88%, CD43 + CD3 - The cell ratio was 99.14%, CD56 + CD94 + The cell ratio was 14.92%, CD45 + CD94 + The cell ratio was 13.35%. It can be seen that on the 20th day of NK cell differentiation culture of hemogenic endothelial cells, NK cell differentiation was basically completed. In Comparative Examples 2 and 4, the cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells were CD45 + CD56 + The cell ratio is slightly lower than that of Example 2, and the fourth and fifth culture media in Comparative Examples 2 and 4 contain serum, and the fourth and fifth culture media in Comparative Example 4 are mixed with two culture media, which makes the operation complicated; in Comparative Examples 2 and 4, the cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells were CD45 + CD94 + cells and CD56 + CD94 + The cell ratio is much smaller than that in Example 2, and the differentiation effect is not good. In the differentiated NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells under different concentrations of BMP4 (0, 2, 20, 10, 5 ng / mL, corresponding to Example 6, Example 4-1, Example 2, Example 4-2, Example 4-3, respectively), CD45+ CD56 + The cell ratios were 34.95%, 58.86%, 96.72%, 90.29%, and 74.29%, respectively; it can be seen that 20 ng / mL of BMP4 is more conducive to NK cell differentiation. Similarly, the bright field cell observation of differentiated NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells under different concentrations of BMP4 (0, 2, 10, 5 ng / mL, corresponding to Example 6, Example 4-1, Example 4-2, and Example 4-3, respectively) is shown in Figure 7: Under low concentrations (0-2 ng / mL) of BMP4, the cells are almost not differentiated, and no suspension cell secretion phenomenon occurs, while under high concentrations (10 ng / mL) of BMP4, the cells have suspension cell secretion; it can be seen that 5-20 ng / mL of BMP4 is more conducive to NK cell differentiation.
[0427] Table 1 Antibody details
[0428] Effect Example 2
[0429] The NK cells collected on the 20th day of the NK cell differentiation culture of hemogenic endothelial cells in Example 2 were transferred to a culture medium containing IL2 (containing 1 μM UM171, 1 μM SR1, 10 ng / ml IL15, 20 ng / ml SCF and 50 ng / ml The cells were cultured in a basal medium containing IL2 (interleukin 2), wherein the basal medium is IMDM medium containing 1% (v / v) non-essential amino acids, 1% (v / v) glutamine, 50 μg / mL vitamin C, and 2% (v / v) B27 medium supplement without vitamin A) for 5 days, and the cultured medium containing NK cells (iPS-NK) was collected into a centrifuge tube and centrifuged in a centrifuge at 1500 rpm for 5 minutes. The NK cell supernatant was collected into a centrifuge tube and the cell supernatant was detected according to the instructions of the IFN-γ ELISA kit (purchased from Stemcell, catalog number: 7664-93-9). The secretion of IFN-γ was then detected in a microplate reader (the same conditions (refer to the treatment method of iPS-NK cells in this embodiment) were used to complete the P Post-culture treatment of B-NK cells: NK cells were transferred to a culture medium containing IL2 and cultured for 5 days. The cultured culture medium containing NK cells (iPS-NK) was collected into a centrifuge tube and centrifuged at 1500 rpm for 5 minutes. The NK cell supernatant was collected into a centrifuge tube) and the supernatant of peripheral blood-derived NK cells (PB-NK, Saili Bio) was collected as a control. The results are shown in Figure 8: The NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2 after 5 days of the above-mentioned culture had a concentration of IFN-γ secreted by NK cells of 10417.25 pg / mL, which is similar to the secretion amount of IFN-γ secreted by peripheral blood-derived NK (PB-NK) after the same treatment. It can be seen that the NK cells obtained by the present invention have a strong function of secreting IFN-γ.
[0430] Effect Example 3
[0431] The tumor cells (Hela cells) with a cell density of 80% were digested and counted with AO / PI. 5×10 cells were added to each well of a 96-well plate. 4 Cells were seeded and allowed to adhere for 5 hours.
[0432] After 5 hours, the NK cells collected on the 20th day of NK cell differentiation culture of the hemogenic endothelial cells in Example 2 were cultured in the IL2-containing medium described in Example 2 for 5 days. The NK cell-containing medium (IMDM-iNK) was collected into a centrifuge tube (the peripheral blood-derived NK cells (PB-NK, Sai Li Bio) treated with the same conditions (refer to the IL2-containing medium described in Example 2) were used as a control), placed in a centrifuge and centrifuged at 1500 rpm for 5 minutes, the supernatant was discarded, and the cells were resuspended in the IL2-containing medium in Example 2, and then AO / PI counting was performed. The NK cells and tumor cells after counting were divided into different ratios (cancer cell:NK The cells were inoculated at a ratio of 1:0, 1:1, 1:3, 1:5, and 1:10 for cancer cell:NK cell. After co-culturing for 18 hours, the supernatant was aspirated and 100 μL of fresh IL2-containing culture medium described in Example 2 was added to each well. 10× CCK8 was added to the culture medium in advance. The culture medium was incubated in an incubator at 37°C and 5% CO2 for 1.5 hours. The 96-well plate was removed from the incubator and the fluorescence value was measured using a microplate reader to detect the killing effect of NK cells on tumor cells. The results are shown in Figure 9: When the cancer cell:NK cell ratio was 1:1, 1:3, 1:5, and 1:10, the killing rates of the NK cells in Example 2 against Hela cells were 17%, 45%, 67%, and 80%, respectively, which were comparable to the killing rates of peripheral blood-derived NK cells (PB-NK) (33%, 57%, 76%, and 76%). It can be seen that the NK cells obtained by the present invention have a good tumor cell-killing function.
[0433] Effect Example 4
[0434] The flow chart of this embodiment is shown in FIG10 , specifically as follows: 5 days in advance (D-5), 1.3×10 U87 glioma cells were injected into the 5 -1.5×10 5 After the mouse tumor model was successfully established (D0), the mice were divided into 6 groups, 4 mice in each group, and each group was given three times, as follows: ①.PBS group (mouse tumor model mice, injected with equal amount of PBS), ②.TMZ group (mouse tumor model, injected with temozolomide, once every seven days, 5 mpk each time, positive control), ③.negative control group (mouse tumor model, injected with equal amount of PBS containing 10 μM IL15 and 20 μM IL12, once every seven days), ④.i-NK group (mouse tumor model, each mouse was injected with 5×10 5 / μL of iPS-NK cells, once every seven days, 5μL each time. The preparation method of i-NK cells is as follows: the culture medium containing NK cells collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells in Example 2 is collected into a centrifuge tube, placed in a centrifuge and centrifuged at 1500 rpm for 5 minutes, the supernatant is discarded, and then 10mL of PBS containing 10μM IL15 and 20μM IL12 is used to resuspend the cells, the cell suspension is passed through a 40μM cell sieve to ensure that the cells are in a single cell state, the cells are placed in a centrifuge and centrifuged at 1500 rpm for 5 minutes, the supernatant is discarded, and then 5mL of PBS containing 10μM IL15 and 20μM IL12 is used to resuspend the cells, and the cells are counted by AO / PI), ⑤.PB-NK group (mouse tumor model, each mouse is injected with 5×10 5 / μL of PB-NK cells, once every seven days, 5μL each time. The preparation method of PB-NK cells is as follows: the culture medium containing peripheral blood-derived NK cells (PB-NK) is collected into a centrifuge tube, placed in a centrifuge and centrifuged at 1500 rpm for 5 minutes, the supernatant is discarded, and then the cells are resuspended in 10mL of PBS containing 10μM IL15 and 20μM IL12, the cell suspension is passed through a 40μM cell sieve to ensure that the cells are in a single cell state, the cells are placed in a centrifuge and centrifuged at 1500 rpm for 5 minutes, the supernatant is discarded, and then the cells are resuspended in 5mL of PBS containing 10μM IL15 and 20μM IL12, and the cells are counted by AO / PI), ⑥.i-NK+TMZ drug group (mouse tumor model, each mouse is injected with 5×10 5 / μL of i-NK cells and 5mpk of TMZ, once every seven days, 5μL each time injection), the mouse survival results are shown in Figure 11: the mice in the PBS control group and the negative control group basically all died around D40-D50 days, the survival rate of the mice in the i-NK group was significantly higher than that in the chemical small molecule drug TMZ group, and slightly lower than that in the natural NK cell group (PB-NK group), while the survival rate of the mice in the i-NK+TMZ combination group was significantly better than that in the natural NK group. It should also be noted that when the i-NK cells acted alone, one of the four mice in the group survived until the end of the experiment (D150), indicating that the mouse was basically cured. It can be seen that the NK cells prepared by the present invention have a good anti-tumor effect, and when used in combination with other anti-tumor drugs, they have a synergistic effect, further enhancing the anti-tumor effect of the NK cells prepared by the present invention.
[0435] Effect Example 5
[0436] During the differentiation of stem cells into hemogenic endothelial cells, low-attachment 96-well plates were used to ensure the uniformity of EB spheres and thus improve the differentiation efficiency. According to the method of Example 2, 2×10 cells were initially plated per 96-well plate. 5 The number of iPSC cells seeded per well was 1.009×10 8 -1.0465×10 8 NK cells (NK cells were collected on the 20th day of NK cell differentiation culture of hemogenic endothelial cells. The results are shown in Figure 12. From the initial iPSC cells to the final harvested mature NK cells, the cell number has expanded by more than 500 times, and the usual NK cell expansion step is no longer required, which greatly facilitates cell transplantation and disease treatment). In addition, the differentiated NK cells were cryopreserved using a cryopreservation solution ( CS10, purchased from stem cell technologies) were cryopreserved (cell concentration was 1×10 7 / mL, that is, 1mL of freezing solution contains 1×10 7 The cells were frozen in a cryopreservation method in which the cell-containing cryopreservation solution was cooled to -80°C in a programmed cooling box, placed in a -80°C refrigerator for 24 hours, and then placed in a liquid nitrogen tank for 1 week. The cell viability was still high (Figure 13).
[0437] Example 5. Evaluation of the sensitivity response of different GBM cell lines to TMZ
[0438] Clinically, GBM tumor cells can exhibit both TMZ-sensitive and TMZ-resistant responses. This example evaluated the TMZ-responsiveness of different GBM tumor cell lines. TMZ-sensitive GBM (U87) and TMZ-resistant GBM (T98G) cells were purchased from Zhejiang Meisen Cell Technology Co., Ltd. U87 and T98G cells were cultured in DMEM (Gibco, 11965084) supplemented with 10% FBS (cellmax, SA211.02).
[0439] 5.1. Sensitivity of GBM to Different Concentrations of TMZ
[0440] A. Cell plating
[0441] U87 and T98G cells were cultured and grown to 80%-90% confluency. Trypsin (Biyuntian, C0201-100 mL) was added to the digestion solution and incubated at 37°C for 5 min. Two volumes of DMEM medium (Gibco, 11965084) were added to terminate the digestion. The cell suspension was transferred to a centrifuge tube and centrifuged at 300g for 5 min. The cell pellet was resuspended in DMEM medium and counted by AOPI staining (AO (acridine orange) / PI (propidium iodide)). Based on the counting results, the cell suspension density was adjusted to 1×105 Cells / mL. Based on grouping requirements, add the cell suspension to a 96-well plate at 100 μL / well. Then, place the 96-well plate in a 37°C incubator and culture overnight.
[0442] B.TMZ Configuration
[0443] Take TMZ powder (Sigma, T2577-25MG), add an appropriate volume of DMSO to dissolve, and prepare a TMZ stock solution with a concentration of 100mM; first prepare the highest concentration of TMZ (5000μM): take 225μL TMZ stock solution, dilute it with 4.5mL DMEM culture medium, and then use serial dilution method to obtain TMZ working solutions with concentrations of 1000μM, 500μM, 200μM, 100μM and 10μM, respectively.
[0444] C. TMZ drug treatment
[0445] After overnight culture of U87 and T98G cells, when they were observed to be attached and in the logarithmic growth phase, 100 μL / well of TMZ working solution of the corresponding working concentration was added according to the group settings. The cells were then returned to the incubator and cell viability and number were detected after 72 hours.
[0446] D. Cell Viability Assay
[0447] use Luminescent Cell Viability Assay Kit (Promega, G7572) was used according to the manufacturer's instructions. The solution was mixed with DMEM medium in a 1:1 ratio to prepare the working solution. The working solution was added to a 96-well plate, 50 μL / well, and incubated at room temperature in the dark for 10 min. PRO) to detect chemiluminescence.
[0448] The test results are shown in Figure 14(A). As the TMZ concentration gradient increases, the number of U87 cells decreases significantly, indicating a sensitive response. The number of T98G cells begins to decline significantly above 500μM, indicating a sluggish response. At 200μM TMZ, the number of viable U87 cells is approximately 50%, while the number of viable T98G cells remains above 80%. At 500μM TMZ, the number of viable U87 cells is approximately 40%, while the number of viable T98G cells remains at 70%. The sensitivity difference ranges from 100μM to 500μM.
[0449] 5.2. GBM sensitivity to TMZ treatment at different times
[0450] The test and detection scheme were the same as in Example 5.1, and the TMZ concentration was selected to be the sensitive interval concentration of 300 μM in Example 5.1.
[0451] As shown in Figure 14(B), the viable cell count of U87 cells decreased significantly with prolonged TMZ treatment, reaching less than 40% at 72 hours. In contrast, T98G cells were less affected by TMZ, maintaining a viable cell count above 80% at 72 hours. These results indicate that U87 cells are TMZ-sensitive GBM and T98G cells are TMZ-resistant.
[0452] Figure 14(C) shows the microscopic examination of drug-resistant GBM (T98G) cells treated with TMZ (300 μM) for 48 hours, and Figure 14(D) shows the microscopic examination of sensitive GBM (U87) cells treated with TMZ (300 μM) for 48 hours. Microscopic examination results showed that, compared with the DMSO control, after 48 hours of TMZ (300 μM) treatment, T98G cell growth was not significantly different, while U87 cell growth was significantly inhibited.
[0453] Example 6. Drug-resistant GBM (T98G) is able to resist TMZ-induced cell cycle arrest
[0454] After TMZ is absorbed into tumor cells, it acts on DNA, causing DNA alkylation damage, which in turn leads to DNA double-strand breaks or crosslinks, arresting the cell cycle and triggering tumor cell proliferation arrest or apoptosis. To investigate the mechanism by which drug-resistant GBM cell lines resist TMZ, a cell cycle assay was performed to examine the effect of TMZ on the cell cycle of different GBM cell lines.
[0455] A. Cell culture and treatment: The experimental procedures for U87 and T98G cell culture and TMZ treatment are shown in Example 5. The TMZ concentration used in this example is 300 μM.
[0456] B. Preparation of cell samples: Use the Biotech Cell Cycle Kit (Biyotime, C1052) according to the manufacturer's instructions. Take 1×10 6 Place 100 cells in a centrifuge tube and set aside. Centrifuge at 1000g for 3-5 minutes to pellet the cells. Aspirate the supernatant, add 1 mL of pre-chilled PBS, resuspend the cells, and transfer to a 1.5 mL centrifuge tube. Centrifuge the cells and aspirate the supernatant.
[0457] C. Cell Fixation: Add 1 mL of ice-cold 70% ethanol, mix thoroughly by pipetting, and fix at 4°C for 30 minutes. Centrifuge at approximately 1000g for 3-5 minutes to pellet the cells. Aspirate the supernatant and resuspend the cells in approximately 1 mL of ice-cold PBS. Centrifuge again to pellet the cells and aspirate the supernatant.
[0458] D. Preparation and staining of propidium iodide (PI) staining solution:
[0459] Refer to Table 2 and prepare an appropriate amount of PI staining solution according to the number of samples to be tested.
[0460] Table 2. Preparation of PI staining solution
[0461] Note: In this example, PI staining solution was prepared based on 12 samples.
[0462] Staining: Add 0.5 mL of PI staining solution to each tube of cell sample, slowly and thoroughly resuspend the cell pellet, and incubate at 37°C in the dark for 30 minutes. Store at 4°C or on ice in the dark. Perform flow cytometry analysis within 24 hours of staining.
[0463] E. Flow cytometric detection and analysis: Red fluorescence and light scattering were detected using a flow cytometer (Agilent, Novocyte 3000) at an excitation wavelength of 488 nm. Cellular DNA content and light scattering analysis were performed using appropriate analysis software (Agilent, Novoexpress).
[0464] After PI enters the cell nucleus, it binds to DNA and produces fluorescence. The intensity of PI is positively correlated with the DNA content in the cell. The peak on the left of each flow cytometer represents DNA in the G1 phase of the cell cycle (2N), the peak on the right represents DNA in the G2 / M phase (4N), and the peak in the middle represents DNA being synthesized in the S phase (between 2N and 4N). As shown in Figure 15(A), after TMZ treatment, DNA in the G2 / M phase of sensitive GBM (U87) cells gradually accumulated over time. Compared with the control DMSO-treated cells, the amount of DNA in the G2 / M phase increased (16.86% at 24 hours, 23.22% at 48 hours, and 40.01% at 72 hours), indicating that the cell cycle was arrested in the G2 / M phase. In contrast, as shown in Figure 15(B), after TMZ treatment, the amount of DNA in the G2 / M phase of resistant GBM (T98G) cells did not change much and remained similar to the DNA content in the control DMSO-treated group. The above data indicate that TMZ can induce cell cycle arrest in GBM cells, while drug-resistant GBM (T98G) can resist this cell cycle arrest.
[0465] Example 7. TMZ-induced upregulation of a series of immune activation-related ligands in drug-resistant GBM tumor cells
[0466] Immune surveillance is a key mechanism for identifying and eliminating tumor cells. The dynamic expression of immune activation-related proteins on tumor cell membranes is crucial for immune cell recognition or escape. This study further investigated the expression changes of immune-related proteins in GBM while resisting TMZ, laying a theoretical foundation for immunotherapy.
[0467] A. GBM cell culture and treatment: T98G cell culture procedures are as described in Example 5. Cells were grown to 80%-90% confluency, then trypsinized and incubated at 37°C for 5 minutes. Two volumes of DMEM medium were added to terminate digestion, and the cell suspension was transferred to a centrifuge tube and centrifuged at 300g for 5 minutes. The cell pellet was resuspended in DMEM medium and counted using the AOP. Based on the count results, the cell suspension density was adjusted to 1×10 5 cells / mL, and then add an appropriate volume of TMZ stock solution (100 mM) to the cell suspension to make the TMZ concentration in the cell suspension 1000 μM. The cells were seeded into a 24-well plate, 500 ml / well.
[0468] B. Antibody incubation and flow cytometry detection of immune-related ligands
[0469] The cells treated with TMZ for 48 hours were dissociated with trypsin digestion solution, centrifuged, and the supernatant was discarded. The corresponding antibodies shown in Table 3 were added and incubated at room temperature for 30 minutes. The cells were washed with PBS, centrifuged, resuspended, and detected by flow cytometry.
[0470] Table 3. Antibodies targeting immune activation
[0471] GBM tumor cell immune activation ligands are important targets for immune cell surveillance and can even activate NK cells. As shown in Figure 16, after 48 hours of TMZ treatment, flow cytometry revealed varying degrees of upregulation of various immune activation ligands. These data suggest that upregulation of a range of immune activation ligands may lead to enhanced NK cell killing, providing a theoretical basis for the combined use of TMZ and immune cells to treat drug-resistant GBM.
[0472] Example 8: TMZ induces upregulation of GBM immune-related ligand expression, thereby triggering a stronger immune response in iPSC-NK cells
[0473] Further in vitro killing studies were conducted to test the effects of NK cells combined with TMZ on GBM tumor cells to explore the possibility of combined drug therapy. The NK cells used in this example were derived from NK cells differentiated from human induced pluripotent stem cells (iPSCs).
[0474] 8.1. In vitro Directed Differentiation of Human Induced Pluripotent Stem Cells (iPSCs) into NK Cells
[0475] In this example, human induced pluripotent stem cells (iPSCs) were prepared using CTS TM CytoTune TM -iPS 2.1 Sendai virus reprogramming kit (CTS TMCytoTune TM -iPS 2.1 Sendai Reprogramming Kit, Catalog No.: A34546) is a human induced pluripotent stem cell (iPSC) prepared from human peripheral blood cells, but the human induced pluripotent stem cells and their preparation in the present invention are not limited thereto and can include human induced pluripotent stem cells and their preparation methods from common known sources in the art.
[0476] A. iPSCs were cultured in a low-adhesion 96-well plate to obtain embryoid bodies. 2×10 5 iPSC cells were evenly distributed in a 96-well plate and seeded into a low-adhesion 96-well plate (coning, 3474) using StemFit Basic 03 medium (Ajinomoto, StemFitBasic03Liquid A / B / rHu BFGF) (first culture medium) containing 10 μM Y27632·2HCl (selleck, S6390) and cultured for 1 day to form embryoid bodies.
[0477] B. Mesoderm differentiation: After one day, the culture medium was changed to mesoderm differentiation medium and cultured for two days.
[0478] Mesoderm differentiation medium (secondary medium): RPMI1640 (Gibco, 22400-089), supplemented with 1% non-essential amino acids (Gibco, 11140050), 1% glutamine (Gibco, 35050-061), 50 mg / mL vitamin C (Sigma, S4226), 2% (v / v) B27 medium supplement without vitamin A (Gibco, 12587-010), 20 ng / mL BMP4 (R&D, 314-BP) and 3 μM CHIR-99021 (selleck, S1263).
[0479] C. Hemogenic endothelial cell differentiation: After 2 days, the mesoderm differentiation medium was replaced with hemogenic endothelial differentiation medium and cultured for 2 days.
[0480] Hemogenic endothelial differentiation medium (third medium): RPMI1640 (Gibco, 22400-089), supplemented with 1% non-essential amino acids (Gibco, 11140050), 1% glutamine (Gibco, 35050-061), 50 mg / mL vitamin C (Sigma, S4226), 2% (v / v) B27 medium supplement without vitamin A (Gibco, 12587-010), 5 ng / mL BMP4 (R&D, 314-BP), 50 ng / mL VEGF (Novoprotein, C083), 50 ng / mL bFGF (Sino Biological, 10014-HNAE), and 10 μM SB431542 (selleck, S1067).
[0481] D. NK cell differentiation-1. After 2 days, collect the embryoid bodies in the low-adhesion 96-well plate into a 50 mL centrifuge tube, allow the cells to settle naturally for 1-2 minutes, discard the supernatant, and leave about 10 mL of supernatant in the centrifuge tube. Then add about 40 mL of NK cell differentiation medium 1, gently pipette to mix the cell spheres, and transfer them to a T225 culture flask for 7 days.
[0482] NK cell differentiation medium 1 (fourth medium): IMDM medium (Gibco, 12400-053), supplemented with 1% non-essential amino acids (Gibco, 11140050), 1% glutamine (Gibco, 35050-061), 50 mg / mL vitamin C (Sigma, S4226), 2% (v / v) B27 medium supplement without vitamin A (Gibco, 12587-010), 5 ng / mL BMP4 (R&D, 314-BP), 10 ng / mL VEGF (Novoprotein, C083), 20 ng / mL SCF (Novoprotein, GMP-CD53), 5 ng / mL IL3 (PeproTech, 200-03), 10 ng / mL IL15 (Sino Biological, GMP-10360-HNCE), 20 ng / mL IL7 (Sino Biological, GMP-11821-HNCE), 10 ng / mL FLT3L (PeproTech, 300-19).
[0483] E. NK cell differentiation-2. After 7 days of culture, NK cell differentiation medium 2 was added and cultured for another 7 days.
[0484] NK cell differentiation medium 2 (fifth medium): IMDM medium (Gibco, 12400-053), supplemented with 1% non-essential amino acids (Gibco, 11140050), 1% glutamine (Gibco, 35050-061), 50 mg / mL vitamin C (Sigma, S4226), B27 medium supplement without vitamin A (Gibco, 12587-010), 5 ng / mL BMP4 (R&D, 314-BP), 10 ng / mL VEGF (Novoprotein, C083), 20 ng / mL SCF (Novoprotein, GMP-CD53), 10 ng / mL IL15 (Sino Biological, 10360-HNCE), 20 ng / mL IL7 (Sino Biological, 11821-HNCE), 10 ng / mL FLT3L (PeproTech, 300-19), 1 μM UM171 (APExBIO, A8950), 1 μM SR1 (selleck, S2858), 30 μM NAC (Sigma, A9165).
[0485] F. NK cell differentiation-3. After 7 days of culture, NK cell differentiation medium 2 was added again and cultured for another 7 days.
[0486] G. NK cell activation and expansion. Collect differentiated NK cells and centrifuge them at 1500 rpm for 10 minutes. Then resuspend the cells in 5 mL of NK cell activation and expansion medium. Pass the cell suspension through a 70 mm cell sieve to filter the cells. Centrifuge the filtered cell suspension again at 1500 rpm for 5 minutes. Resuspend the cells in 5 mL of NK cell activation and expansion medium. Adjust the starting density to 1 × 10 6 Cells / mL were cultured with medium replacement every 3-4 days for 7-10 days. This was used for subsequent functional testing.
[0487] Activation expansion medium: CTS NK-Xpander Medium (GIBICO, A5019001), supplemented with 500 IU of IL-2 (PeproTech, 200-02), 10 ng / mL of IL-15 (Sino Biological, 10360-HNCE), 10 ng / mL of IL-18 (Sino Biological, 10119-HNCE), and 5% hAB (Shanghai Hengyuan Biotechnology, HY120-AB).
[0488] Finally, the harvested iPSC-NK cells (iNK) were characterized by flow cytometry. The results, shown in Figure 17, demonstrate that the NK cells differentiated from iPSCs in vitro exhibited ideal viability (91.51%), purity (97.68%), and expression of functional receptors (purity greater than 75%). Information on antibodies used for NK cell characterization is shown in Table 4.
[0489] Table 4. Antibodies against immune activation-related targets
[0490] 8.2. iPSC-NK cells combined with TMZ exhibit stronger degranulation activity
[0491] The iPSC-NK cells differentiated in Example 8.1 were co-cultured with GBM tumor cells or TMZ-treated GBM tumor cells to detect changes in immune response intensity (degranulation activity). The experimental design is shown in Table 5.
[0492] Table 5. Degranulation activity test design
[0493] Preparation of target cells: The culture methods of T98G and U87 cells were as described in Example 5. The target cells in the TMZ pretreatment group were treated with 1000 μM TMZ 48 hours in advance and set aside.
[0494] Target cell plating: Centrifuge the target cells of each group in advance, resuspend and count, and dilute to 5×10 5 The target cells were inoculated at a density of 100 cells / mL in the corresponding well plates according to the grouping settings.
[0495] Effector cell delivery: iNK cells were centrifuged, resuspended and counted, and the cell density was diluted to 5×10 5 cells / mL, inoculate 100 μL / well of effector cells into the corresponding well plate and mix gently by pipetting.
[0496] Blank control: 100 μL of activation amplification medium was added to the blank control wells.
[0497] Positive control: Add PMA / io (Biolegend, 423301) to 5 mL of activation amplification medium at a ratio of 1:500, pipette to mix thoroughly, and add to the positive control wells at 100 μL / well.
[0498] Incubation with CD107a antibody (BD, 560664): Prepare 1 μL of antibody suspension per well, dilute with 10-fold volume of activation and expansion medium, mix thoroughly by pipetting, and add 10 μL of antibody suspension to each well.
[0499] Place the prepared culture plate in the incubator and incubate for 1 hour.
[0500] Add Golgi blockers: Dilute golgistop (BD, 51-2092KZ) and golgiplug (BD, 51-2301KZ) to 10 times the volume of complete culture medium at a ratio of 0.2 μL / well and add 10 μL to each well. Place the culture plate in the incubator and continue incubation for 3 hours.
[0501] After the culture, the cells in the well plate were transferred to the corresponding 1.5 mL centrifuge tubes, centrifuged at 800 g for 5 minutes, the supernatant was discarded, and the cells were resuspended in 100 μL PBS. 1 μL CD56 flow cytometry antibody was added to each tube, incubated at room temperature in the dark for 20 minutes, centrifuged at 800 g for 5 minutes, the supernatant was discarded, and the cells were resuspended in 100 μL PBS for flow cytometry detection.
[0502] As shown in Figure 18(A), for the drug-resistant strain T98G, co-culture of iNK and target cells triggered a certain proportion of degranulation activation, and the expression of CD107a increased from the baseline of 11.98% to 16.50%. In combination with TMZ, the expression of CD107a was significantly increased to 30.85%, indicating that the combination of iNK and TMZ enhanced the immune activation ability of NK cells.
[0503] As shown in Figure 18 (B), for the sensitive strain U87, co-culture of iNK and target cells triggered a stronger degranulation activation, and the expression of CD107a increased from 12.83% of the background to 38.29%. In combination with TMZ, the expression of CD107a was further increased to 60.22%.
[0504] The above results indicate that TMZ can trigger a stronger iNK immune response against GBM tumor cells.
[0505] Example 9: iPSC-NK combined with TMZ has stronger tumor cell killing activity against drug-resistant GBM (T98G)
[0506] Furthermore, this example explored the in vitro efficacy of iPSC-NK combined with TMZ by monitoring the killing of tumor target cells.
[0507] A. GBM tumor cell T98G culture, digestion and plating methods refer to Example 5.
[0508] B. TMZ configuration: The method for treating cells is shown in Example 5. In this example, 1000 μM was used for pretreatment for 48 hours.
[0509] C. Preparation of iPSC-NK cells see Example 8.
[0510] D. Co-culture killing. According to the effector-target ratio (1:8, 1:4 and 1:1), take an appropriate volume of iNK cells in the expansion culture (note that the iNK cell viability should be maintained above 90%) and count them by AOPI. According to the counting results, adjust the cell suspension density to 1×10 5 cells / mL. 1×10 4 After the 96-well T98G cells were attached to the wall (6 hours after re-digestion and inoculation), the NK cell suspension was added to the T98G well plate according to the experimental group design. After incubation for 18 hours, the cells were used T98G cell viability was detected using a luminescence cell viability assay kit. Three replicates were performed in each group.
[0511] E. Cell viability assay. At the set time points (8, 16, 24, 48 hours), cells were collected. Luminescent Cell Viability Assay Kit was used according to the manufacturer's instructions. The solution was mixed with DMEM medium in a 1:1 ratio to prepare the working solution. The working solution was added to a 96-well plate at 50 μL / well and incubated at room temperature in the dark for 10 min. The chemiluminescence was then detected using a microplate reader.
[0512] F. Calculation of killing rate. Killing rate (%) = (fluorescence intensity of the intact group - fluorescence intensity of the injured group) / fluorescence intensity of the intact group * 100%. t-test: p < 0.05 is marked *, p < 0.01 is marked **.
[0513] The results are shown in Figure 19. At 8, 16, 24, and 48 hours after co-culture, TMZ had a weak killing effect on drug-resistant GBM (T98G), with only about 10% killing at 48 hours (blank column). iNK has a significant killing effect on target cells, and it increases over time and as the effect-target ratio increases (gray column). Importantly, the killing of target cells by the iNK combined with TMZ group was significantly improved at the corresponding time points and effect-target ratio (black slash column). The above results indicate that although drug-resistant GBM (T98G) has a resistance effect to TMZ, TMZ combined with iNK cells will have a stronger tumor killing activity against it.
[0514] Example 10: Synergistic effect of NK cells from other sources (NK92, PB-NK) combined with TMZ on drug-resistant GBM
[0515] Given that immune target recognition and tumor immune killing are fundamental tumor immune mechanisms, not limited to iPSC-NK cells, this example also uses NK cells from other sources for in-depth research and comparison. The NK92 cell line was purchased from Zhejiang Meisen Cell Technology Co., Ltd., and the peripheral blood-derived PB-NK cells were purchased from Shanghai Heyousheng Biotechnology Co., Ltd.
[0516] A. NK92 cell line culture and expansion. NK92 culture medium: CTS NK-Xpander Medium (GIBICO, A5019001), supplemented with 500 IU of IL-2 (PeproTech, 200-02) and 5% hAB (Shanghai Hengyuan Biotechnology, HY120-AB). 5 -5×10 5 The cells were inoculated at a density of 10 cells / mL, and the medium was changed halfway every 48 hours. The cells were cultured in a 37°C incubator.
[0517] B. PB-NK cell culture and expansion. PB-NK culture medium: CTS NK-Xpander Medium (GIBICO, A5019001), supplemented with 500 IU of IL-2 (PeproTech, 200-02), 10 ng / mL of IL-15 (Sino Biological, 10360-HNCE), 10 ng / mL of IL-18 (Sino Biological, 10119-HNCE), and 5% hAB (Shanghai Hengyuan Biotechnology, HY120-AB). 1×10 6 The cells were seeded at a density of 10 cells / mL, and the medium was changed halfway every 2-3 days. The cells were cultured in a 37°C incubator and expanded for 14 days for subsequent functional testing.
[0518] Finally, the harvested NK92 cells and PB-NK cells were characterized by flow cytometry. For detailed procedures and reagents, see Example 8. As shown in Figure 20, the harvested, expanded NK92 cell lines and PB-NK cells both exhibited viability exceeding 85%, purity exceeding 85%, and high expression of functional receptors. PB-NK cells exhibited a lower NKp44 expression of approximately 14%. This is likely due to the dynamic expression of different functional receptors in NK cells derived from different peripheral blood sources, resulting in individual variability, which is normal.
[0519] C. In vitro GBM killing by NK cells from different sources combined with TMZ. The efficacy of iPSC-NK, NK92, and PB-NK cells combined with TMZ was investigated. The in vitro killing method was described in Example 9. The effector-target ratio (E:T) was 1:1, and the co-culture time with GBM tumor cells was set to 8 hours. The groups were set as shown in Table 6.
[0520] Table 6. Experimental design of NK cells combined with TMZ to kill drug-resistant GBM
[0521] The test results are shown in Figure 21. Eight hours after co-culture, TMZ had almost no killing effect on drug-resistant GBM (T98G) (blank column). iNK, NK92, and PB-NK all had a killing effect on target cells (gray column), with a killing rate of 40-60%, and the killing of target cells by NK cells from various sources combined with TMZ was significantly improved (black slash column), with a killing rate greater than 60%. Further analysis and comparison of the killing activity of iNK, NK92, and PB-NK revealed that the in vitro killing activity of iNK combined with TMZ was superior to that of NK cells from other sources combined with TMZ. The above results indicate that compared with NK cells from other sources combined with TMZ, iPSC-derived NK cells combined with TMZ have stronger tumor killing activity against drug-resistant GBM (T98G).
[0522] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.
Claims
1. A kit comprising a second culture medium, a fourth culture medium and a fifth culture medium; wherein: The second culture medium is a basal culture medium containing a BMP signaling pathway activator; The fourth culture medium is a basic culture medium comprising at least one, at least two, at least three or at least four of the following: a BMP signaling pathway activator, a vascular endothelial growth factor, a colony stimulating factor, and an interleukin; The fifth culture medium is a basic culture medium containing at least one, at least two, at least three, at least four, at least five or at least six of the following: BMP signaling pathway activator, vascular endothelial growth factor, colony stimulating factor, interleukin, stem cell agonist, stem cell expander.
2. The kit according to claim 1, wherein The stem cell agonist comprises at least one of UM171 and UM729; preferably, the stem cell agonist comprises UM171; and / or The stem cell expander comprises at least one of SR1 and PD98059; preferably, the stem cell expander comprises SR1.
3. The kit according to claim 1 or 2, The kit further comprises a third culture medium, which is a basic culture medium comprising at least one, at least two or at least three of the following: a BMP signaling pathway activator, a growth factor, and a TGFβ / ALK inhibitor.
4. The kit according to any one of claims 1 to 3, The kit further comprises a first culture medium, which is a basal culture medium comprising a ROCK inhibitor.
5. The kit according to any one of claims 1 to 4, The second culture medium is a basal culture medium containing a BMP signaling pathway activator and a GSK3 inhibitor.
6. Use of the kit according to any one of claims 1 to 5 in preparing embryoid bodies, preparing mesodermal cells, preparing hemogenic endothelial cells, preparing natural killer (NK) cells, preparing products of inducing stem cells to differentiate into embryoid bodies, preparing products of inducing stem cells to differentiate into mesodermal cells, preparing products of inducing stem cells to differentiate into hemogenic endothelial cells, and preparing products of inducing stem cells to differentiate into NK cells.
7. A method for inducing stem cells to differentiate into natural killer (NK) cells, the method comprising the step of using the kit according to any one of claims 1 to 5.
8. The method of claim 7, The method comprises: Step (1) culturing stem cells to obtain embryoid bodies; Step (2) performing mesodermal differentiation culture on the embryoid bodies to obtain mesodermal cells; Step (3) performing hemogenic endothelial differentiation culture on the mesoderm cells to obtain hemogenic endothelial cells; Step (4) culturing the hemogenic endothelial cells in the fourth culture medium and the fifth culture medium of the kit defined in any one of claims 1 to 5 to obtain NK cells; Preferably, the culturing in step (1) is carried out in the first culture medium of the kit defined in claim 4; Preferably, the culturing in step (2) is carried out in the second culture medium of the kit defined in claim 5; Preferably, the culturing in step (3) is carried out in the third culture medium of the kit defined in claim 3; Preferably, the culturing time in step (1) is 12-36 hours; Preferably, the culturing time in step (2) is 24-72 hours; Preferably, the culturing time in step (3) is 48-144h; Preferably, in step (4), placing the hemogenic endothelial cells in the fourth culture medium and the fifth culture medium of the kit defined in any one of claims 1 to 5 for culturing is placing the hemogenic endothelial cells in the fourth culture medium and the fifth culture medium of the kit defined in any one of claims 1 to 5 for culturing in sequence; Preferably, the hemogenic endothelial cells are cultured in the fourth culture medium for 96-192 hours; Preferably, the hemogenic endothelial cells are cultured in the fifth culture medium for 144-432 hours.
9. A natural killer (NK) cell prepared by the kit of any one of claims 1 to 5 or the method of claim 7 or 8; Preferably, CD3 - CD45 + CD56 + The cell content is more than 90%; Preferably, CD3 - CD56 + Nkp44 + The cell content is more than 90%; Preferably, CD3 - CD56 + Nkp30 + The cell content is more than 85%.
10. A pharmaceutical composition comprising the NK cell according to claim 9; Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. The pharmaceutical composition of claim 10 , further comprising an anti-tumor drug.
12. Use of the NK cell according to claim 9 or the pharmaceutical composition according to any one of claims 10 to 11 in the preparation of a drug for preventing and / or treating tumors.
13. A pharmaceutical combination for treating glioblastoma, comprising an active ingredient comprising natural killer (NK) cells and a chemotherapeutic agent, wherein the chemotherapeutic agent comprises temozolomide (TMZ).
14. The pharmaceutical combination of claim 13, wherein the glioblastoma is resistant to TMZ.
15. The pharmaceutical combination of claim 13 or 14, wherein the NK cells are unmodified NK cells.
16. The pharmaceutical combination according to any one of claims 13 to 15, wherein the NK cells are NK cells derived from induced pluripotent stem cells (iPSCs).
17. The pharmaceutical combination of any one of claims 13-16, wherein the NK cells are prepared by the kit of any one of claims 1-5 or the method of claim 7 or 8.
18. The pharmaceutical combination of any one of claims 13-17, further comprising other chemotherapeutic agents selected from anticancer agents, metabolic antagonists, DNA demethylating agents, antitumor agents derived from plants, alkylating agents, antimetabolites, anticancer antibiotics, topoisomerase inhibitors, mitotic inhibitors, differentiation agents, and hormone therapeutic agents.
19. The pharmaceutical combination of claim 18, wherein the other chemotherapeutic agent is selected from carmustine, lomustine, vorinostat, mebendazole, imatinib mesylate, AG119, or any therapeutic derivatives thereof.
20. The pharmaceutical combination according to any one of claims 13 to 19, wherein the active ingredient does not comprise trimetrexate.
21. The pharmaceutical combination of any one of claims 13-20, wherein the active ingredient does not comprise an immune checkpoint inhibitor.
22. The pharmaceutical combination according to any one of claims 13 to 21, which is a kit.
23. Use of the pharmaceutical combination according to any one of claims 13 to 22 in the preparation of a medicament for treating glioblastoma.
24. The use of claims 13-23, wherein The chemotherapeutic agent is administered before, after, or simultaneously with the administration of the NK cells.
25. The use of claims 13-24, wherein the chemotherapeutic agent is administered 8 to 72 hours before, 8 to 72 hours after, or 8 to 72 hours before and after the administration of the NK cells.
